CALL FOR ABSTRACTS

Abstract Submission Deadline: November 16, 2023
Late-Breaking and Clinical Trials Abstract Submission Deadline: January 8, 2024

Continuing Medical Education Activity - AMA PRA Category 1 Credits™ available
ABOUT THE COVER IMAGE:
The AACR Annual Meeting 2024 covers the entire spectrum of cancer research, prevention, etiology, and treatment of the 200+ diseases we call cancer. The cover depicts this year’s theme, "Inspiring Science • Fueling Progress • Revolutionizing Care".
©2024 American Association for Cancer Research
AACR ANNUAL MEETING 2024 KEY DATES

September 2023
- September 12, 2022: Membership Application Deadline for Early Access to Housing Reservations
- September 19, 2023: Early Access to Housing Reservations Opens for Members
- September 26, 2023: Housing Reservations Open to Nonmember Attendees
- September 29, 2023: Abstract Submission Opens
- September 30, 2023: Extended Nomination Deadline for AACR Scientific Achievement Awards

October 2023
- October 3, 2023: Application Deadline: NextGen Stars
- October 24, 2023: Meeting Registration Opens

November 2023
- November 1, 2023: Abstract Submission Deadline for AACR New Drugs on the Horizon Sessions
- November 10, 2023: Membership Application Deadline for Prospective Regular Abstract Sponsors and Scholar-in-Training Award Applicants
- November 16, 2023: Regular Abstract Submission Deadline (11:59 p.m. ET)
- November 16, 2023: Application Deadlines:
  - AACR Global Scholar-in-Training Awards
  - AACR Scholar-in-Training Awards
  - AACR Patient Advocates in Cancer Research Awards
- November 30, 2023: Application Deadlines:
  - AACR Minority Scholar in Cancer Research Awards
  - AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Awards
  - AACR Women in Cancer Research Scholar Awards
  - AACR Undergraduate Scholar Awards
- December 8, 2023: 2023 Membership Application Deadline for Early Registration Rate
- December 15, 2023: Regular Abstract Status Notifications Sent
- December 15, 2023: Early Registration Deadline (lowest rates)
- December 18, 2023: Late-Breaking and Clinical Trials Abstract Submission Opens
January 2024

January 3, 2024  Membership Application Deadline for Prospective Late-Breaking and Clinical Trials Abstract Sponsors

January 8, 2024  Late-Breaking and Clinical Trials Abstract Submission Deadline (11:59 p.m. ET)

January 9, 2024  Manuscript Submission Deadline for Simultaneous Publication Consideration (Regular Abstracts)

January 17, 2024  Online Itinerary Planner Available (tentative)

January 25, 2024  Regular Abstract Scheduling Notifications Sent

March 2024

March 1, 2024  Cancellation Deadline for Registration Refunds (less $125 processing fee)

March 5, 2024  Regular Abstract Titles and Texts Posted to Online Itinerary Planner (4:30 p.m. ET)

March 5, 2024  Late-Breaking and Clinical Trials Abstract Titles Posted to Online Itinerary Planner (4:30 p.m. ET); Abstract Texts Embargoed until April 5, 2024

March 15, 2024  Annual Meeting App Available for Download (tentative)

March 15, 2024  Registration Deadline: Undergraduate Student Caucus and Poster Competition

April 2024

April 1, 2024  Membership Application Deadline to Register for the Annual Meeting at the Member Rate Onsite

April 5, 2024  Onsite Registration Opens at San Diego Convention Center (12:00 p.m. PT)

April 5, 2024  AACR Annual Meeting Begins (3:00 p.m. PT)

April 5, 2024  Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App (12:00 p.m. PT)

February 2024

February 5, 2024  Manuscript Submission Deadline for Simultaneous Publication Consideration (Late-Breaking and Clinical Trials Abstracts)

February 6, 2024  Submission Deadline: Final Data for Clinical Trial Placeholder Abstracts

February 9, 2024  Regular Abstract Withdrawal Deadline

February 9, 2024  Membership Application Deadline for Advance Registration Rate

February 12, 2024  Late-Breaking and Clinical Trials Abstract Notifications Sent

February 16, 2024  Advance Registration Deadline (discounted rates)

February 23, 2024  Late-Breaking and Clinical Trials Abstract Withdrawal Deadline

February 23, 2024  Housing Reservation Deadline

February 29, 2024  Abstract Submission Deadline: Undergraduate Student Caucus and Poster Competition
With very best wishes and regards,

Keith T. Flaherty, MD, FAACR
Chair, 2024 Program Committee

Christina Curtis, PhD, MSc
Chair, 2024 Program Committee

Philip D. Greenberg, MD, FAACR
President, 2023-2024

Margaret Foti, PhD, MD (hc)
Chief Executive Officer, AACR

Dear Members and Friends of the AACR,

It is our pleasure to invite you to attend the 115th Annual Meeting of the American Association for Cancer Research® (AACR), which will take place on April 5-10, 2024, in San Diego, California.

The theme of this year’s meeting is “Inspiring Science • Fueling Progress • Revolutionizing Care.” It reflects the breathtaking opportunities in the field of oncology at the current moment, one in which a critical mass of discoveries in basic research and advances in preclinical science are precipitating a revolution in the way cancer is prevented, diagnosed, treated, and cured.

The AACR Annual Meeting is at the hub of that revolution—the place where myriad fields of inquiry intersect to foster new connections, spark new collaborations, and open new frontiers for exploration. The Program Committee Co-chairs have been working hard to develop an outstanding program that maximizes these intersections, including sessions that will showcase concurrent basic science discoveries, clinical advances, computational insights, and technological breakthroughs to highlight the full spectrum of progress against cancer. We are grateful to all of the Program Committee members for their expert guidance, and we look forward to sharing the results of their efforts and those of all the participating scientists in April.

Daily plenary sessions will focus on some of the most exciting recent advances and emerging opportunities in the field, and on the integration of data science in driving progress in cancer science and clinical oncology, including: discovery science in early cancer biology and interception; harnessing technological and computational breakthroughs to fuel new knowledge and revolutionize care; profiling tumor ecosystems; cancer metastasis; and artificial intelligence at the interface of research and trial design. The program will also include a special Presidential Select Symposium that will focus on cancer immunotherapy. Visit AACR.org/AACR2024 for program updates.

This revolution in the etiology, biology, prevention, detection, diagnosis, and treatment of cancer is driven in part by a new generation of cancer scientists. With more than 29,000 graduate students, medical students and residents, and clinical and postdoctoral fellows participating in its programs as Associate Members, AACR is committed to the education, training, and professional advancement of these early-career investigators. This commitment is reflected in the Annual Meeting program, which will include a comprehensive series of career development sessions to sustain and expand the cancer workforce.

In addition, the AACR NextGen Stars program—which will mark its tenth anniversary at the Annual Meeting—offers early-career and early-stage scientists the opportunity to apply for oral presentation slots at the Annual Meeting. AACR Associate Members, as well as Active Members at the assistant professor level or equivalent, are welcome to submit an application and an extended abstract to the NextGen Stars program by October 3, 2023.

The robust scientific and career development program will be preceded by a comprehensive slate of educational sessions and methods workshops. This educational program, which will begin at 3:00 p.m. on Friday, April 5, and run through Saturday, April 6, will present state-of-the-art concepts and technologies across a broad range of areas by leaders in their fields. Please keep the educational program in mind when registering and making your travel plans.

In addition to the program of invited speakers, the meeting will feature more than 6,000 presentation slots to accommodate proposed papers. Meritorious proposed papers will receive consideration for oral presentation in Minisymposia. We encourage you and your colleagues to submit your abstracts by the November 16, 2023, deadline to be considered for oral or poster presentation.

The proposed program will also feature more than 200 clinical trials—including nearly 40 oral presentations in high-profile Clinical Trial Plenary Sessions and Clinical Trial Minisymposia. Clinical trialists are urged to consider the AACR Annual Meeting 2024 as a premier presentation outlet for their practice-changing work that will improve patient care. The submission deadline for clinical trials abstracts is January 8, 2024.

We hope you will join us in person in San Diego or virtually and be a part of the impending revolution in cancer science and care. Please check the AACR website (AACR.org/AACR2024) regularly for program updates and announcements. We look forward to receiving your abstract submissions and to your active participation in the AACR Annual Meeting 2024.

With very best wishes and regards,

Keith T. Flaherty, MD, FAACR
Chair, 2024 Program Committee

Christina Curtis, PhD, MSc
Chair, 2024 Program Committee

Philip D. Greenberg, MD, FAACR
President, 2023-2024

Margaret Foti, PhD, MD (hc)
Chief Executive Officer, AACR
Why You Should Attend the World’s Most Important Cancer Research Meeting

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology and genetics, translational, and clinical studies; to survivorship, population sciences, and advocacy. You will be exposed to the latest developments in all areas of cancer research, form new collaborations, and learn how to apply exciting new concepts, tools, and techniques to your own research.

This year’s program, with the theme of “Inspiring Science • Fueling Progress • Revolutionizing Care,” will be a comprehensive, cutting-edge scientific event that you will not want to miss!

The AACR Annual Meeting 2024 Will Highlight:

• Educational Program—More than 65 highly valuable Educational Sessions and Methods Workshops will once again be offered beginning on Friday, April 5. Access to these important sessions led by cancer experts is available to all attendees by purchasing the Educational Program Pass during registration.

• Clinical Trials—Included in the growing science-based clinical research program at the AACR Annual Meeting, clinical trials will once again be presented in Clinical Trials Plenary Sessions, Minisymposia, and Poster Sessions. A total of 243 clinical trials were presented at last year’s Annual Meeting, including 36 oral presentations of highly rated abstracts.

• NextGen Stars Program—Now in its tenth year, the NextGen Stars oral presentations program will showcase early-career scientists who are AACR Associate Members and early-career and early-stage Active Members up to the level of assistant professor or equivalent. AACR is committed to providing early-career scientists with key opportunities to showcase their research and network with other cancer experts. To apply, submit your abstract and supporting materials by October 3, 2023. Details can be found at AACR.org/AACR2024.

• Wrap-Up Plenary Session—The meeting will close with key opinion leaders presenting the most exciting highlights from the meeting and providing visionary remarks about cancer research opportunities in the future. The Wrap-Up Plenary Session will take place on Wednesday, April 10, 12:00 p.m.-1:30 p.m.

• Advancing Commercialization and Fostering Entrepreneurship—Building upon the excitement and interest in the special entrepreneurship sessions held during the 2021, 2022, and 2023 AACR Annual Meetings, a new AACR program spotlighting advances in commercialization and future directions in oncology product development will be held on Thursday, April 4, and Friday, April 5, 2024, prior to the start of the Annual Meeting. This new program will attract leading pharmaceutical companies, small- and mid-size biotechs, and the venture capital and investment community. Additional information and separate registration details will be available later this year on this exciting new program.

A special track devoted to the education of academic researchers interested in entrepreneurship will once again be included in the AACR Annual Meeting program.

• Cancer Research Awareness Night with the San Diego Padres—Join the San Diego Padres and the Chicago Cubs on Tuesday night, April 6, for Cancer Research Awareness Night sponsored by the AACR. There will be a special giveaway for those who buy tickets through the AACR website and proceeds will go towards funding cancer research through AACR’s grants program. Tickets will go on sale in early 2024.
Why You Should Submit an Abstract

The AACR Annual Meeting is the premier event for presenting the cutting-edge cancer science that is shaping the future of cancer research and delivering cures to communities. Every abstract that is accepted for publication in the online Proceedings of the AACR is presented at the AACR Annual Meeting as a proffered paper, and all abstracts are considered for oral presentation in Minisymposia.

Opportunities to give an oral presentation and simultaneously publish your work in a high-impact AACR journal are available for abstract presenters. See page 26 for more details.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2024 press program, which garners widespread national and international news coverage. See page 21 for more details.

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world.
Beginning at 3:00 p.m. on Friday, April 5, and continuing all day Saturday, April 6, 2024, a program of Educational Sessions and Methods Workshops will be presented. The program on Saturday will conclude with the Plenary Session titled, Discovery Science in Early Cancer Biology and Interception (4:15 p.m.-6:15 p.m.) The Opening Ceremony and the Opening Plenary Session will take place on Sunday morning, April 7. The meeting will conclude at 1:30 p.m. on Wednesday, April 10. The 2024 Program in Progress follows:

**Educational Program: Educational Sessions and Methods Workshops**

The Educational Program is an integral part of the meeting and provides attendees with an opportunity to expand their knowledge base in new and exciting fields. Add the Educational Program Pass to your registration to access this important program. The Educational Program consists of more than 65 unique sessions covering all areas of cancer research and features updates on critical topics and new technologies. As part of these sessions, the following popular sessions and topics will be included. Watch for more information at [AACR.org/AACR2024](http://AACR.org/AACR2024).

- **Tumor Immunology and Immunotherapy for Nonimmunologists.** This exciting session is part of the yearly programming presented at the AACR Annual Meeting and organized in conjunction with the AACR Cancer Immunology Working Group. This popular session provides a comprehensive review of hot topics in the field and allows ample time for questions from the audience.

- **Chemistry to the Clinic.** This multi-part series, organized in conjunction with the AACR Chemistry in Cancer Research Working Group, provides meeting attendees with foundational knowledge of critical elements of the cancer drug design and development process, such as lead optimization and identification of molecular targets and novel drug modalities.

- **Clinical Trial Design.** Over the course of three consecutive sessions, these Methods Workshops will provide attendees with a historical and methodologic understanding of clinical trials and demonstrate how to design an appropriate trial to answer the scientific questions presented by emerging treatments.

- **Data Science.** Several sessions will focus on exciting advances and emerging opportunities in cancer research. Sessions will also explore the integration of data science in advancing cancer science and medicine.

Additional details will be posted at [AACR.org/AACR2024](http://AACR.org/AACR2024).

**ABOUT THE IMAGE ABOVE**

EGFR is abundantly expressed in many solid tumors, and TGFβ is known to sustain tumor progression by suppressing the immune response to the tumor and promoting the metastatic potential of cancer cells. The bifunctional molecule BCA101 targets EGFR and simultaneously sequesters TGFβ. BCA101 durably suppresses tumor growth and is currently under investigation in clinical trials. *Cancer Research*, June 1, 2023; 83(11).
Plenary Sessions

Saturday, April 6, 2024
Discovery Science in Early Cancer Biology and Interception
Chair: Daniel D. De Carvalho, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
Don W. Cleveland, UC San Diego School of Medicine, San Diego, CA
Margaret A. Goodell, Baylor College of Medicine, Houston, TX
Michael B. Kastan, Duke Cancer Institute, Durham, NC
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

Sunday, April 7, 2024
Opening Plenary Session: Inspiring Science, Fueling Progress, Revolutionizing Care
Chairs: Keith T. Flaherty, Harvard Medical School, Boston, MA; Christina Curtis, Stanford University, Stanford, CA
Carolyn R. Bertozzi, Stanford University, Stanford, CA
Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, CA
Jakob N. Kather, Technical University Dresden, Dresden, Germany
Aviv Regev, Genentech, Inc., South San Francisco, CA

Monday, April 8, 2024
Profiling Tumor Ecosystems in Native Tissue Context
Chair: Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY
Michael Angelo, Stanford University, Stanford, CA
Susan Bullman, Fred Hutchinson Cancer Center, Seattle, WA
Joakim Lundeberg, Science for Life Laboratory, Stockholm, Sweden
Peter K. Sorger, Harvard Medical School, Boston, MA

Tuesday, April 9, 2024
Evolution of the Genome, Microenvironment, and Host through Metastasis
Chair: Cyrus M. Ghajar, Fred Hutchinson Cancer Center, Seattle, WA
Sarah-Maria Fendt, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
Christoph A. Klein, University of Regensburg, Regensburg, Germany
David C. Lyden, Weill Cornell, New York, NY
Dana Pe’er, Memorial Sloan Kettering Cancer Center, New York, NY

Wednesday, April 10, 2024
AI at the Interface: Accelerating Evidence Generation, Advancing Disparities Research, and Improving Trial Design
Chair: Eric J. Topol, The Scripps Research Institute, La Jolla, CA
Thomas Clozel, Owkin, Geneva, Switzerland
Maryellen J. Giger, University of Chicago, Chicago, IL
Mia A. Levy, Foundation Medicine Inc, Cambridge, MA
Anant Madabhushi, Emory University, Atlanta, GA

Wednesday, April 10, 2024
AACR Annual Meeting 2024 Highlights: Vision for the Future
Chairs: Keith T. Flaherty, Harvard Medical School, Boston, MA; Christina Curtis, Stanford University, Stanford, CA
Speakers to be announced

Presidential Select Symposium

Monday, April 8, 2024
Presidential Select Symposium: Cancer Immunotherapy - Where Do We Go from Here?
Chair: Philip D. Greenberg, Fred Hutchinson Cancer Center, Seattle, WA
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
K. Christopher Garcia, Stanford University, Stanford, CA
Nir Hacohen, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, NY
**Major Symposia**

AACR-Bayard D. Clarkson Symposium: Cellular Plasticity in Malignancy - Co-option of Developmental Processes

Antigen Discovery and Validation for Cancer Vaccines

Approaches to Improve Quality of Life and Long-term Outcomes for AYA and Adult Cancer Survivors

Biomarkers in the Post-TCGA Era: Where Are We Now?

Cancer Metabolism Across Scales: From Organelles to Organs

CAR Cells 3.0

CDK4/6 Inhibitors: Not Just for Breast Cancer Anymore

Cellular Competition in Premalignancy and Cancer

Cellular Therapies in Pediatric Solid Tumors

Chromatin and Cancer: From Mechanisms to Therapy

Crosstalk within the Tumor Ecosystem

Current Challenges in the Use of Chemical Probes in Cancer Research and Target Validation

DNA Repair and Host Immune Response

Eavesdropping on the Immunosuppressive Crosstalk between the Myeloid and T Cell Compartments

Emerging Therapeutic Modalities in Induced Proximity beyond Protein Degradation

Engineered Cells: Including NK Cells, Macrophage, and Nonspecific T Cells

Epigenetics and Chromatin Regulation in Cancer

Evidence, Gaps, and Solutions to Advance Health Behavior Practices to Improve Cancer Survivorship and Prevent Death

From Genome Structure to Function

Genomic Instability and Metastasis: Dangerous Liaisons or Two Sides of the Same Coin?

Genomics-based Predictive Biomarkers for Radiotherapy and Radioimmunotherapy

How Does Obesity Influence the Anticancer Effects of Immunotherapy?

IDH: Bench to Bedside Translation

Immunometabolism

Interventional Studies during Cancer Treatment to Improve Symptoms and Outcomes

Metabolic Drivers of Radioresistance

Metabolic Regulation of the Cancer Cell State

Microbiome and Treatment Response

Minorities in Cancer Research Scientific Symposium

Molecular Glues, Protacs, and Beyond: Discovery and Early Preclinical Advances

Neoadjuvant Therapies

Novel Immune Checkpoints: Beyond PD1 and CTLA4

Optimizing Cancer Vaccines through Advances in Immunogenomics and Immunopeptidomics

Pediatric Cancer: Mechanisms and Translation

RNA Modifications in Malignancy

Role of the Neuronal Microenvironment in Cancer

Shared Risk Factors and Mitigation Strategies for Cancer, Cardiovascular Disease, and Metabolic Diseases: What Can We Learn?

Socioeconomic Disparities Contributing to Cancer Outcomes Disparities

Somatic Evolution in Normal Tissues: Causes and Consequences

T Cell-based Therapies for Solid Tumors

Targeting Aberrant Transcription in Pediatric Cancer

Targeting CDK Activity in Cancer: The Wide World beyond Cyclin D-CDK4/6

Targeting Mitosis in Cancer: Emerging Strategies

Tumor Dormancy: From an Illusory Phenomenon to Clinical Reality

Tumor Microbiome

Understanding and Predicting Tumor Evolution

Unexpected Mechanisms for Success with Checkpoint Inhibitors
PROGRAM (cont’d)

Advances in Diagnostics and Therapeutics
Advances in ADCs, Novel Payloads, and New Targets
Chemical Biology Approaches to Tackle Undruggable Targets
Drugging Transcription Factors
Ex Vivo Functional Diagnostics
Novel Targeting T-cell Bispecific Approaches for the Treatment of Cancer
Oligometastasis: Curable Metastatic State?
Radiotheranostics: The NEW Nuclear Medicine
Targeting KRAS beyond G12C
Understanding Cancer Cachexia

Advances in Hematologic Malignancies
Advances in Lymphoma
Basic, Translational, and Clinical Advances in ALL and AML
Immune Microenvironment in Hematologic Malignancies
Precursors to Hematologic Malignancies
Relapse after Allogeneic Bone Marrow Transplant
Resistance to Immunotherapy in Myeloma

Advances in Organ Site Research
Androgen Receptor as a Pro-Differentiation and Oncogenic Transcription Factor
Colorectal Cancer Screening: New Tests, Sensitivities, and Specificities
Impact of Tumor Heterogeneity on the Evolution of Pancreatic Cancer
Inflammatory Breast Cancer
Lung Cancer in Nonsmokers
Novel Strategies for Early Detection of Ovarian Cancer
Overcoming the Barriers: Therapeutic Options for Glioblastoma (GBM)
Surgical Innovations in Breast Cancer
Translational and Clinical Advances in Pancreatic Cancer
Uveal Melanoma

Advances in Population Sciences
Early-onset Cancers: Challenges and Opportunities for Prevention
Progress since COVID-19 on Cancer Prevention Rates in Populations

Advances in Prevention Research
Application of Precision Medicine to Cancer Prevention
Current Tools and Approaches for Studying the Role of the Microbiome in Cancer Prevention
Understanding Precursor Lesions to Optimize Prevention

Advances in the Science of Cancer Disparities
Genomic Research in Ancestrally Diverse and Admixed Populations
Molecular Profiling in Breast Cancer and Racial/Ethnic Minorities

Advances in Technologies
Accelerating Precision Diagnostics through AI: Radiomics and Digital Pathology
Frontiers in Computational Oncology: Harnessing Multimodal Data for Biological Insight
Mutational Processes in Cancer: From Replication Stress to Complex Genomic Rearrangements
New Liquid Biopsy Technologies for Detection and Characterization of Cancer
Next Generation Functional Genomics for Target Discovery
Novel Experimental Models for Functional Precision Genomics
Unlocking Spatial Complexity: Harnessing Machine Learning for Spatial Biology Insights
Forums and Special Sessions

AACR-ASCO Joint Session
AACR-JCA Joint Session
The Biology of Aneuploidy
Bridging the Gaps between Discovery and Lifestyle Changes for Cancer Prevention Translation
Breaking the Obesity-Cancer Link: The Role of New Weight Loss Drugs
Cancer Research Capacity Building and Outcomes for Low- and Middle-income Countries
Criteria and Best Practices for the Development, Selection, and Use of Chemical Probes
The Impact of Financial Toxicity on Cancer Occurrence and Outcomes and Possible Solutions
Lessons Learned from Pediatric Cancers
Mechanisms of Resistance: Why Have We Failed to Turn Cold Tumors Hot?
Opportunities and Challenges in Leveraging Real-World Data to Accelerate Evidence Generation
Will an Increased Trust in Science Help Us Address Pressing Cancer Research Issues Such As Cancer Health Care Disparities and Clinical Trials Participation?

New Drugs on the Horizon Sessions

Held in collaboration with the AACR Chemistry in Cancer Research Working Group each year, this special three-part session series features first disclosures of the chemistry and biology of small- and large-molecule agents that are currently being or will soon be actively investigated in clinical trials for the treatment of cancer. The abstract submission and review process is distinct from the regular and late-breaking abstract submission processes. The deadline to submit an abstract for consideration is November 1. For more information, visit the New Drugs on the Horizon page on AACR.org/AACR2024.

Science and Public Policy Program

Decisions made by policymakers in Washington, DC, have a direct impact on cancer research and the progress being made against cancer in the United States and throughout the world. The AACR sponsors sessions with policymakers, academic researchers, patient advocates, cancer survivors, and industry representatives to foster dialogue about emerging topics in science and health policy, and regulatory science and policy.

The Science and Health Policy Track includes sessions that will provide attendees with an opportunity to learn about how policy impacts science and vice versa. Science policy sessions will examine the current political environment affecting federal funding for the NIH and NCI, including highlighting ways for scientists to get involved in advocating for robust, sustained, and predictable budget increases.

Health policy sessions will explore how scientific evidence can inform policy on cancer prevention and control and what impact policies are having on patients and communities. Past health policy sessions have covered topics such as e-cigarettes and tobacco control measures, the Affordable Care Act, and ways to prevent and control pathogen-related cancers, such as increasing the use of the human papillomavirus (HPV) vaccine.

The Regulatory Science and Policy Track includes informative sessions designed to highlight recent regulatory developments and provide an open forum for the consideration of issues that the FDA faces as the agency seeks to accelerate the pace of approval of safe and effective treatments for patients with cancer. These sessions offer an opportunity for attendees to discuss cutting-edge issues in cancer drug, biologic, and diagnostic regulation with stakeholders from academia, industry, advocacy, and government. Past regulatory science and policy topics have included strategies for increasing participation of underrepresented populations in clinical trials, guidance for using real-world evidence to support clinical trials during the COVID-19 pandemic, regulatory considerations for developing liquid biopsy tests, implications of site-agnostic therapy approval for drug development, and applications for artificial intelligence/machine learning in regulatory decision-making.

The Science of Survivorship Track includes sessions highlighting new and high-value areas of research to address the array of challenges facing long-term cancer survivors. Sessions invite trans-sector discussion among the survivor and advocacy communities, basic and clinical researchers, industry representatives, health care providers, and government officials. Past science of survivorship topics have included aging and cancer, long-term survivorship in vulnerable populations, development of new survivorship models, patient-reported outcomes, data sharing, and patient engagement.
Submit Your Clinical Trials Abstracts to the AACR Annual Meeting 2024

Become a part of our growing science-based clinical research program at the AACR Annual Meeting and help us showcase how research continues to transform the lives of cancer patients.

Why You Should Submit

• Numerous and unique oral presentation opportunities, including:
  - Four Clinical Trials Plenary Sessions offering companion presentations discussing the science behind the trials presented
  - Three Clinical Trials Minisymposia
• Poster presentations
• Opportunities for extensive national media coverage through the AACR press program
• Opportunities to publish a manuscript in one of the AACR’s highly regarded journals, including possible simultaneous publication with your abstract presentation
  - Review the FAQ relating to simultaneous publication in the AACR Journals for more information (AACR.org/AACR2024journals)
  - Contact aacrpublications@aacr.org with any questions
• No restrictions on presenters if the presentation is CME-compliant

What to Submit

• Any phase (0, first-in-human, I, II, III, or any combination) abstract from national or international clinical trials
• Trials for solid tumors or blood cancers in adult and pediatric patients
• Promising ongoing trials, or unique trial designs that have not yet yielded results. Select the Clinical Trials in Progress category (CT01).
• Encore clinical trials presentations that have been presented solely in abstract form, including publication in conference proceedings. Submissions must include significant additional data from the previous presentation (as determined by the AACR Clinical Trials Committee).
• See page 30 for clinical trials (CT) abstract categories and visit AACR.org/AACR2024 for submission guidelines.

When to Submit

• Submit your completed or placeholder abstract(s) by the January 8, 2024 deadline for clinical trials and late-breaking abstracts. The clinical trials (CT) abstract categories will not be available for submissions for the November 16, 2023 deadline.
• Final results and conclusions for placeholder abstracts are due by February 6, 2024.

AACR Annual Meeting 2023

| 36 | CLINICAL TRIALS ABSTRACTS PRESENTED IN PLENARY SESSIONS AND MINISYMPOSIA |
| 138 | CLINICAL TRIALS ABSTRACTS PRESENTED IN POSTER SESSIONS |
| 69  | CLINICAL TRIALS IN PROGRESS ABSTRACTS PRESENTED IN POSTER SESSIONS |
| 243 | TOTAL CLINICAL TRIALS ABSTRACTS PRESENTED |
In support of its mission to promote the education and training of cancer scientists and clinicians, and to cultivate a highly skilled and diverse cancer research workforce, the AACR provides AACR Annual Meeting attendees at all career stages—from high school and undergraduate students to senior investigators—with opportunities to advance their careers. For more information about any of the professional development opportunities that follow, visit AACR.org/PAS.

NextGen Stars

The AACR Annual Meeting 2024 marks the 10th anniversary of the prestigious and competitive AACR NextGen Stars program. Early-career scientists can apply to give a presentation in a Major Symposium or Advances Session at the AACR Annual Meeting 2024. Speaking slots are limited and are only available to AACR Associate Members and to AACR Active Members who are not above the level of assistant professor or equivalent. The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career and early-stage scientists at the AACR Annual Meeting and to support their professional development and advancement.

The deadline to submit applications is 5:00 p.m. U.S. ET, October 3, 2023. Applications consist of an extended abstract (limit 8,000 characters), a CV, and a letter of recommendation from a P.I., department head, or another mentor who is familiar with the applicant’s work. Applicants selected as NextGen Stars for 2024 will receive travel support and complimentary registration for the meeting. Details can be found at AACR.org/AACR2024 under the “NextGen Stars” tab.

Professional Advancement Series

Exclusive Member Benefit

The Professional Advancement Series of sessions has long been an integral part of the AACR Annual Meeting experience and is dedicated to the education, training, and career advancement of cancer research investigators at all stages of their careers. A collaborative effort each year by the AACR Science Education and Career Advancement Committee, Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, Associate Member Council (AMC), and the Publications Committee, these sessions provide several interactive and engaging professional development and career advancement opportunities to investigators at all levels, including students, early-career scientists, and early-stage investigators.

All Professional Advancement Sessions are free and exclusive to AACR members. There is no cost to join the AACR as an Associate Member (graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to a career in cancer research) or Student Member (undergraduate and high school students). If you are not an AACR member, you are strongly encouraged to join the AACR and take advantage of the opportunity to attend these sessions and receive the many other benefits of membership, including the privilege of sponsoring abstracts, significantly reduced member registration rates, and more. Visit AACR.org/Membership to apply today!

The full listing of sessions in the Professional Advancement Series to be held at the Annual Meeting 2024 will be announced in the fall. Space is limited and participation is available on a first-come, first-served basis for all sessions except the Grant Writing Workshop and Personalized Career Conversations, which require advance registration. Visit AACR.org/PAS for session updates and to preregister.
PRODUCTIVE PEER REVIEW: IMPROVING SCIENCE WHILE AVOIDING COMMON PITFALLS

Moderated by Editors of AACR scientific journals, this interactive session will focus on how to become a proficient reviewer and how to effectively respond to reviewers’ comments.

GRANT WRITING WORKSHOP

This session aims to provide new investigators (postdoctoral fellows and new faculty) with practical tools to write competitive grants. Focus is on how to write well for grants, how to structure an aims page to help the reviewer “get” all the information you want them to, and how to write an aims page that makes a reviewer excited about your grant. We will address different types of grants from NIH (Rs, Ks, Fs etc.) as well as grants from other countries. We will also discuss Summary Statements (“pink sheets”) and have a roundtable where participants can network and ask experienced scientists questions about the grants they are working on. Preregistration is required.

PERSONALIZED CAREER CONVERSATIONS

This session provides a unique opportunity for early-career AACR Associate members to participate in 15-minute one-on-one conversations with distinguished cancer researchers from across various sectors—including academia, government, and industry. Distinguished session chairs will moderate informal discussions on important topics in the general session while one-on-one discussions are underway, and participants will have an opportunity to informally network with peers and members of the organizing groups to gain additional perspectives about various career topics. Preregistration is required to participate in one-on-one conversations.

HOW TO DESIGN A SUCCESSFUL CAREER PATH IN CANCER RESEARCH: THE DO’S AND DON’TS FOR EARLY-STAGE INVESTIGATORS

This session is intended for early-stage investigators to acquire skills and develop key strategies in order to avoid “pitfalls” and develop “alternative” tactics to enhance the probability of success in their first independent leadership position. This session is designed specifically for those who have already made the transition from trainee to the next career stage inside and outside of academia. This is an absolute must-attend session for all early-stage investigators.

NAVIGATING THE PATH TO A SUCCESSFUL CAREER IN CANCER RESEARCH

This exciting and interactive session and networking reception provides a forum in which students, early-career researchers, and early-stage investigators can discuss critical career development topics and survival skills during informal mentored roundtable discussions. Tables with predetermined professional development topics are facilitated by established scientists from a variety of sectors, including academia, government, and industry.

BUILDING AN EFFECTIVE MENTORSHIP TEAM: ESSENTIAL STRATEGIES AT EVERY STAGE IN YOUR CAREER

Navigating a successful career in cancer research, whether in academia, industry, or government, can be daunting. Establishing a team of mentors to guide you along the way is an essential step as you begin your journey. In this highly interactive session, cancer researchers with a strong commitment to mentoring and supporting the professional development of cancer research investigators, will share their knowledge and experience leading mentoring teams. Hear their stories and learn how to build and take full advantage of an effective mentoring team, whether you are a trainee, an early-stage investigator, or a later stage investigator considering a career change.

ADDITIONAL PROFESSIONAL DEVELOPMENT OPPORTUNITIES

PROFESSIONAL DEVELOPMENT WORKSHOP: WOMEN AND POWER—ADVANCING AND SECURING YOUR CAREER IN SCIENCE

Sponsored by The Victoria’s Secret Global Fund for Women’s Cancers, in partnership with Pelotonia and AACR-Women in Cancer Research

This highly interactive, professional development workshop will focus on leadership training for women in science, at all stages of their careers. The four-hour workshop will consist of a plenary session and small group exercises where attendees will hone their ability to recognize their sources of power, understand and leverage their circles of influence to achieve audacious goals, and deepen their connections with female colleagues. The workshop will be led by hfp consulting, a globally-recognized firm that specializes in career development and leadership training exclusively for scientists. Pre-registration is required as space is limited for this special workshop. Visit AACR.org/PAS for session updates and to preregister. Email wicr@aacr.org with questions.
19th Annual Undergraduate Student Caucus and Poster Competition

With more than 250 undergraduate student participants every year, the AACR Undergraduate Student Caucus and Poster Competition continues to be the premier event for undergraduate students attending the AACR Annual Meeting. Now in its 19th year, this program provides undergraduate students with the opportunity to learn more about current research in the cancer field, hear from investigators about educational pathways and career development, explore career options in the cancer field, and compete for the Margaret Foti Foundation Undergraduate Prizes for Cancer Research while presenting research. Undergraduates at all levels are welcome to participate in this highly anticipated program at no cost. To learn more about this exciting opportunity, please visit AACR.org/ScienceEducation or send an email to scienceeducation@aacr.org.

Registration Deadline (nonpresenting): March 15, 2024.

AACR Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers

The Special Program for High School Students promotes interactions between senior cancer scientists and promising students in order to facilitate the contributions of these students to scientific research and the conquest of cancer. Don’t miss this wonderful opportunity to learn about cancer research and careers in biomedical research and medicine. The session is free, but space is limited. Learn more at AACR.org/HighSchoolProgram.

Registration Deadline: March 15, 2024.

CancerCareers.org

AACR’s CancerCareers.org is a year-round career development resource center. The Center provides an unparalleled opportunity for cancer and biomedical research scientists, at all professional levels, and for clinicians who are seeking to advance their scientific careers to be provided with career development resources. Employers who are seeking to recruit highly qualified scientists are of ered the opportunity to utilize the resources available to them on CancerCareers.org as a premier recruiting tool. For more information, visit CancerCareers.org or email customerservice@cancercareers.org.

AACR Annual Cancer and Biomedical Research Career Fair

The AACR Annual Cancer and Biomedical Research Career Fair will take place at the AACR Annual Meeting in San Diego, California on Saturday, April 6, 2024, from 9:00 a.m.-3:00 p.m. Visit CancerCareers.org for more information or to register for the 2024 Career Fair (AACR.org/careerfair), or email careerfair@aacr.org.

Employers will:
• Meet with candidates at all scientific levels
• Post open positions
• Review CVs/resumes

Job seekers will:
• Meet with employers face-to-face from academia, industry, and government institutions
• Upload CVs/resumes on CancerCareers.org
• Sign up for Job Alerts

CancerCareers.org Hub

The AACR provides Career and Professional Development opportunities to scientists at all career levels at the CancerCareers.org Hub. AACR will host several Career Development and recruiting events at the AACR Annual Meeting 2024 beginning on Sunday, April 7 through Wednesday, April 10, 2024, in the CancerCareers Hub, located in the San Diego Convention Center.

The CancerCareers Hub is open during the following hours:
Sunday, April 7 9:00 a.m.-5:00 p.m.
Monday, April 8 9:00 a.m.-5:00 p.m.
Tuesday, April 9 9:00 a.m.-5:00 p.m.
Wednesday, April 10 9:00 a.m.-12:00 p.m.

Create your FREE jobseeker profile account to search for positions, post your CV/resume, create Job Alerts, and take advantage of other features. For more information, visit CancerCareers.org or email customerservice@cancercareers.org.

Networking Hubs

Taking place on Sunday, April 7, from 6:30 p.m.-8:00 p.m., the AACR Networking Hubs will once again of er a “can’t miss” opportunity for young investigators. The Hubs will target several rapidly advancing areas of research. There will be no formal program, but the Hubs of er a fun opportunity to socialize and network with colleagues, potential collaborators, and some of the most respected investigators in the cancer research community. Look for more information in the coming months on the Professional Development Opportunities tab on AACR.org/AACR2024.
The 2024 AACR Exhibit Show will include a wide array of companies with the latest products and services for laboratory and clinical research. Additional areas of interest include the Nonprofit Section, AACR Publications and Publisher’s Row, AACR Advocacy Partners’ Pavilion, and AACR Central, which is the main hub for AACR services.

The exhibits, located adjacent to the poster sessions, make a significant contribution to the educational value of the meeting. Please add time to your overall schedule to visit the Exhibit Show. Complimentary coffee, tea, and soft drinks will be served in the Exhibit/Poster Hall at specified times on each day when exhibits are open.

In addition, great opportunities to connect with exhibitors and other attendees will be available in the Exhibit Hall.

• Visit the Headshot Lounge in the Exhibit Hall to update your headshot for your business card, resume, and social media.
• Enhanced refreshment breaks, featuring a wide variety of specialty snacks, will be served on Monday and Tuesday afternoon. These breaks provide networking to attendees and exhibitors.
• Be sure to participate in the Explore! game, available through the AACR Annual Meeting App. By visiting all participating exhibitors, you will be entered to win an Amazon gift card. Additional information will be available in the App and on the AACR website.
• Located in the Sails Pavilion above the Exhibit Hall, the Exhibitor Spotlight Theaters are reserved by exhibiting companies to present their latest products and services in special 60-minute sessions during exhibit hours. For a full list of presentations, please refer to the AACR Annual Meeting App.

If your organization would like to exhibit and would like to receive an Exhibitor Prospectus, please contact the Exhibits Team at 215-440-9300 or by email at exhibits@aacr.org.

AACR Central

Located in the center of the Exhibit Hall, AACR Central serves as a hub for information and services for attendees and as an event space for various programs. Open during Exhibit Hall hours, AACR Central is home to the Membership Center, MICR Networking and Resource Center, WICR Networking and Resource Center, and information kiosks covering: Scientific Meetings and Workshops; AACR Foundation; AACR Publications; Scientific Review and Grants Administration; Science Policy and Advocacy; and much more. New for 2024! Visit AACR Central and check out the AACR Project GENIE interactive display.

At AACR Central, attendees can:

• Apply for AACR membership, learn more about AACR member benefits, and check on the status of membership.
• Participate in networking events organized by the Associate Member Council (AMC), Minorities in Cancer Research (MICR), Women in Cancer Research (WICR), the Science Education and Career Advancement Committee, and others.
• Find additional information on AACR’s conferences, award programs, advocacy efforts, and the AACR Foundation.
• Pick up copies of Cancer Today, AACR’s peer-reviewed journals, the AACR Cancer Progress Report 2023, and Leading Discoveries magazine.
AACR Shop

Located outside of the Exhibit Hall, the AACR Shop is the place to get your AACR branded swag and show your support for cancer research.

New for 2024, shop the AACR Cancer Research Saves Lives® collection and choose from a wide assortment of AACR t-shirts, golf shirts, sweatshirts, hats, youth and baby apparel, mugs, water bottles, and much more. Stop by in April and purchase an AACR Annual Meeting 2024 branded tee shirt!

All purchases are tax deductible charitable donations, and proceeds go directly to the AACR to support our mission to prevent and cure all cancers.
The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Accreditation with Commendation status by the Accreditation Council for Continuing Medical Education (ACCME). The AACR CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advancing the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer. The AACR Annual Meeting 2024 will be a Continuing Medical Education Activity and AMA PRA Category 1 Credits™ will be available. This is a great opportunity to complete your required credit hours.

Meet Your MOC Point Requirements

If you are a physician, you can meet your Maintenance of Certification (MOC) point requirements at the AACR Annual Meeting 2024. The meeting is CME/MOC accredited. Successful completion of the CME activity enables you to earn MOC points of the American Board of Internal Medicine's (ABIM) Maintenance of Certification program.
Commitment to Cancer Survivors and Patient Advocates

Patient advocates play a crucial role in cancer research. They educate the public about new research discoveries, partner with scientists on cancer research, guide health and regulatory policies, and raise precious funds for cancer research. The AACR celebrates the contributions of patient advocates to cancer research and encourages their attendance and participation at the AACR Annual Meeting.

Patient advocates are offered discounted registration rates to attend the AACR Annual Meeting.

AACR Scientist↔Survivor Program® at the AACR Annual Meeting

Now in its 26th year, the AACR Scientist↔Survivor Program® (SSP) at the AACR Annual Meeting is an education program for patient advocates. Led since its inception by Anna D. Barker, PhD, FAACR, of the Lawrence J. Ellison Institute for Transformative Medicine, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide. The program has a competitive application process which will open in September 2023.

The unique program provides an opportunity for patient advocates to learn about cancer research and network with scientists, physicians, health care professionals, and other advocates. Specifically, patient advocate representatives come together to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

If you are interested in applying for this year’s SSP, please visit AACR.org/SSP2024 or email advocacy@aacr.org.

Patient Advocacy Programs at the AACR Annual Meeting

AACR offers a number of opportunities to encourage bidirectional communication between researchers and patient advocates at the AACR Annual Meeting, including the AACR Partners Pavilion, patient advocate abstracts, Patient Advocates in Research Awards, and patient advocate forums. For more information, please visit AACR.org/patient-advocacy.
Attracting Journalists Worldwide, Generating Major News Coverage

The AACR is the authoritative resource and voice for cancer research, and the AACR Annual Meeting garners the best in national and international news coverage. The AACR Annual Meeting 2023 attracted more than 220 registered reporters and generated more than 6,500 media clips in leading consumer and trade outlets including NBC News, CBS Evening News, CNN, The Wall Street Journal, USA Today, and STAT, among many others.

All abstracts accepted for presentation at the meeting will be considered for inclusion in the official AACR Annual Meeting 2024 press program. For more information on the AACR Annual Meeting press program, please contact Julia Gunther at julia.gunther@aacr.org or Rick Buck at rick.buck@aacr.org.

Utilizing Social Media to Amplify the Conversation

The AACR Annual Meeting 2023 also generated significant social media activity in the cancer research community. Social media highlights included:

- 7,900+ people joining the conversation on Twitter
- 30,000+ tweets about the meeting
- 388,000,000 total impressions

Social media users who are interested in the AACR Annual Meeting 2024 are encouraged to follow and use the meeting hashtag: #AACR24.
Through the generosity of its loyal supporters, the AACR is pleased to provide financial support to meritorious undergraduate students and early-career scientists residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Detailed information about these award programs, including eligibility and selection criteria, is available below.

### AACR Scholar-in-Training Awards

**Exclusive Member Benefit**

Scholar-in-Training Awards are available for Associate Members in good standing who are the presenters of meritorious proffered papers at the AACR Annual Meeting 2024. Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a Scholar-in-Training Award should submit their AACR membership applications by **November 10, 2023**. The AACR Membership Application Form is available on the AACR website at [AACR.org/Membership](https://aacr.org/membership). To apply for a Scholar-in-Training Award, an applicant must first submit an abstract, and then complete a separate award application. While awards will be based on meritorious applications across scientific disciplines, some funding for the AACR Annual Meeting 2024 has been designated to support awards for applicants meeting specific scientific or geographic criteria. For details of the application process and the selection criteria, please visit [AACR.org/SITA](https://aacr.org/sita). Additional information will be posted as it becomes available.

**Application deadline: November 16, 2023.**

### AACR Global Scholar-in-Training Award

Global Scholar-in-Training Awards (GSITA) are available for eligible early-career investigators in countries building cancer research capacities. Applicants must submit an abstract to the AACR Annual Meeting 2024 and then complete a separate GSITA application. Applicants must be Associate Members of the AACR in good standing (membership current through 2023). Student Members completing a Bachelor of Medicine, Bachelor of Surgery (MBBS), or other international undergraduate medical degree equivalent to an advanced medical degree in the United States, are also welcome to apply. Nonmember undergraduate students pursuing an international medical degree, graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a GSITA should submit a Membership Application Form by **November 10, 2023**, before submitting their GSITA application. For additional details and a list of eligible countries, visit [AACR.org/GSITA](https://aacr.org/gsita).

**Application deadline: November 16, 2023.**

### AACR Patient Advocates in Cancer Research Awards

AACR Patient Advocates in Cancer Research Awards are available to patient advocates presenting meritorious abstracts at the AACR Annual Meeting. To apply for this award, an applicant must first submit an abstract, and then complete a separate award application. For more information, please visit [AACR.org/patient-advocacy](https://aacr.org/patient-advocacy).

**Application deadline: November 16, 2023.**
AACR Minority Scholar in Cancer Research Awards

Presenters of proffered papers who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award. This program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally underrepresented in cancer and biomedical research, e.g., African American/Black, Alaskan Native, Hispanic/Latino, American Indian, and Native Pacific Islander. Only citizens of the United States or Canada, or scientists who are permanent residents of these countries, may receive one of these awards. For details or to apply, visit AACR.org/MSA.

Application deadline: November 30, 2023.

AACR Women in Cancer Research (WICR) Scholar Awards

The AACR Women in Cancer Research (WICR) Scholar Award recognizes WICR members who are scientists-in-training and presenters of meritorious scientific papers at the AACR Annual Meeting. The purpose of this award is to increase the scientific knowledge base of WICR members and to encourage them to pursue careers in cancer research. Eligible candidates encouraged to apply include AACR-WICR members who are graduate students, medical students and residents, clinical fellows, and postdoctoral fellows. For details or to apply, visit AACR.org/WSA.

Application deadline: November 30, 2023.

AACR Minority and Minority-Serving Institution Faculty (MMSIF) Scholar in Cancer Research Awards

Full-time underrepresented minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], Tribal Colleges and Universities [TCUs], Predominately Black Institutions [TBCs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at the AACR Annual Meeting are encouraged to apply for this meritorious scholar award.

These awards are intended to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada, or scientists who are permanent residents of these countries, may receive one of these awards. For details or to submit an application, visit AACR.org/MSI.

Application deadline: November 30, 2023.

AACR Undergraduate Scholar Awards

The AACR is pleased to offer this highly competitive award program, which is intended to inspire young, third-year science students to enter the field of cancer research and to provide a unique educational opportunity for these students in the development of their careers in science. Selected students will receive scholar awards to participate in two consecutive AACR Annual Meetings. To learn more about this award program, visit AACR.org/UndergradAwards.

Application deadline: November 30, 2023.
**Proffered Paper Presentation**

All proffered papers that are accepted for poster or oral presentation at the AACR Annual Meeting 2024 **must be presented in person**. Posters will not be presented in electronic format, and remote minisymposium presentations will not be permitted. Presenters who are unable to travel to San Diego to present their proffered paper in person will have the opportunity to designate a coauthor to serve as the presenter. If no coauthors are available to present the paper in person, the abstract must be withdrawn.

Presenters of proffered abstracts that have been selected for oral presentation in a minisymposium must agree to have their presentations recorded and made available to meeting registrants on the virtual meeting platform. Presenters who decline to have their minisymposium presentation recorded will be withdrawn from the session and reassigned to a poster session.

**IMPORTANT**

**Publication of Abstracts in Cancer Research**

In previous years, abstracts accepted for presentation at the AACR Annual Meeting were published in an online-only Proceedings supplement to the AACR journal *Cancer Research* after the conclusion of the meeting. For the AACR Annual Meeting 2024, the Proceedings supplement will be published prior to the meeting in two parts. Part 1 of the online Proceedings (regular abstracts) will be published on Friday, March 22, and Part 2 (clinical trials and late-breaking abstracts) will be published on Friday, April 5. Revised Proceedings supplements containing the full text of embargoed abstracts as well as any late changes will be published in *Cancer Research* approximately one month after the meeting.

Once the abstracts are published in the journal, additional requests for edits and withdrawals cannot be processed. Therefore, abstract authors should carefully read their abstracts before submission to ensure that all authors are listed correctly and that the text is correct. All requests to withdraw or edit abstracts must be received by the following deadlines:

- **Regular Abstracts** (submitted by the November 16 deadline): **Friday, February 9, 2024**
- **Clinical Trials and Late-Breaking Abstracts** (submitted by the January 8 deadline): **Friday, February 23, 2024**

**Special Interest Submissions**

The AACR encourages submission of abstracts in the following categories, which will be given special consideration for oral presentation at the AACR Annual Meeting 2024:

- **Cancer Disparities and Inequities Research.** This abstract subcategory is included in the Population Sciences (PS), Prevention, Early Detection, and Interception (PR), and Science and Health Policy (SHP) categories (see pages 32–33).
- **Studies Using Data from AACR Project GENIE®.** While there is no specific abstract category for abstracts that describe work using AACR Project GENIE®, you can have your abstract considered by selecting “AACR Project GENIE®” as one of your keywords during the submission process.
- **Studies to be Presented by Patient Advocates.** Patient Advocacy and Engagement is a subcategory included in Science and Health Policy (SHP). Patient advocates may submit work to this category or any other category and simply select “Advocacy” as one of the keywords to be considered for a session featuring patient advocates as presenting authors.

**AACR Abstract Submission System**

Authors must submit abstracts for presentation at the AACR Annual Meeting 2024 using the AACR Abstract Submission System, which will be available at [AACR.org/AACR2024](http://AACR.org/AACR2024) beginning September 29, 2023. You can create, modify, and submit abstracts.
until the November 16, 2023, abstract deadline. Complete instructions on the use of the AACR Abstract Submission System will be provided on the website.

The Abstract Submission System has been optimized for the current versions of most browsers. Browsers should be set to enable JavaScript and to accept cookies. Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or aacr@support.ctimeetingtech.com.

Responsibilities of Authors

By submitting an abstract for presentation at the AACR Annual Meeting, abstract authors agree and/or attest to the following:

• Support for Abstract/Verification of Authorship. All authors accept individual responsibility for the accuracy and integrity of statements in their abstract, and the submitting author is required to ensure that all authors have confirmed that all statements are an accurate reflection of the presented data and have agreed to the submission of the abstract and to their being listed as contributors prior to submission. The submitting author is also required to ensure that all relevant contributors to the abstract are included in the list of authors. Authors will be notified of their inclusion on an abstract via email.

• Sponsorship of Abstracts. The submitting author must provide the name of an AACR member who has agreed to sponsor the abstract, and the submitting author must attest that the permission of the member sponsor has been secured prior to initiating an abstract submission. See page 27 for Abstract Sponsorship Regulations.

• Transfer of Copyright. On behalf of all authors, the submitting author must assign and transfer copyright for the abstract to the AACR.

• Presentation of Abstracts. All proffered papers scheduled for presentation at the AACR Annual Meeting 2024 must be presented in person. The submitting author for each abstract must designate a presenter who agrees to register for the meeting and attend the corresponding session to discuss in detail the research presented in the published abstract. If the assigned presenter cannot attend the meeting, the authors are expected to designate a replacement or withdraw the abstract (see page 24).

• Confirmation of No Prior Publication/Presentation. Authors who submit an abstract confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2024.

Exceptions: Encore presentations are permitted for clinical trials abstracts that are submitted for the January 8, 2024, clinical trials deadline. During the submission process, authors of encore clinical trials abstracts must provide the date and name of the meeting at which the original trial abstract was presented. Any other exceptions to this policy are at the discretion of AACR leadership.

Content of Abstracts

Each abstract should contain (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).

Abstract Control Number and Abstract Presentation Number

An Abstract Control Number (e.g., 24-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

The Control Number is for internal reference only. If your abstract is accepted for presentation, it will be assigned a permanent Presentation Number that will be used to identify it in all online and print abstract materials. Please place the Presentation Number on your poster and use it in citations of your published abstract. Do not place the Control Number on your poster.

Financial Relationships of Coauthors

Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of each of your coauthors. For more information on financial relationships, visit AACR.org/CME.

Sponsor Permission and Information

Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” on page 27.
Length of Abstracts

The combined length of the abstract body, title, and tables may not exceed 2,600 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

Abstract Category, Subcategory, and Subclassification

You must select a category, subcategory, and subclassification for your abstract. See pages 29–33 for details.

NEW FOR 2024

Disclosure of Chemical Structures

At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the prof ered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids cocrystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to disclose the complete chemical structures of the compounds used at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, the chemical structures must be disclosed during the presentation. If the chemical structure cannot be disclosed at the time of presentation, then the abstract should be withdrawn.

Submission Fee

Each abstract submitted must be accompanied by a US$75 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

Abstract Deadline

The deadline for abstract submissions is 11:59 p.m. U.S. ET, Thursday, November 16, 2023. Abstracts submitted after the deadline will not be considered by the Program Committee. No significant changes may be made to abstracts after the November 16, 2023, deadline.

NOTE: Submitting an abstract for presentation at the AACR Annual Meeting 2024 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting at AACR.org/AACR2024.

Late-Breaking Abstract Deadline

The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 8, 2024. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted. Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

Clinical Trials Abstract Deadline

The deadline for clinical trials abstracts (including placeholder abstracts) is 11:59 p.m. U.S. ET, Monday, January 8, 2024. Final data for placeholder abstracts are due Tuesday, February 6, 2024. Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts.

Publication Opportunities

Authors may consider submitting a manuscript based on their meeting abstract. Manuscripts submitted by the deadlines noted in the FAQ (AACR.org/AACR2024journals) can be considered for publication simultaneously with the AACR’s Annual Meeting, provided major revisions are not required. In addition, manuscripts can be considered for publication beyond the simultaneous opportunity. For more information on all publication opportunities in an AACR journal, please contact the AACR Publishing Division at aacrpublishations@aacr.org.

Presentation of Prof ered Papers at the AACR Annual Meeting

Every prof ered abstract that has been accepted for publication in the online Proceedings must have a corresponding in-person presentation at the meeting. Specifically, the author listed as the presenter for an accepted prof ered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Scientific Programs Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Scientific Programs Department at abstractchanges@aacr.org.
GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS (cont’d)

Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

- The withdrawal of the abstract from the session
- The removal of the abstract from the online Proceedings
- The loss of future sponsorship privileges for the sponsor of the abstract
- The loss of future abstract submission/authorship privileges for the presenter of the abstract

Deadline for Withdrawal of Abstracts

Requests to withdraw regular abstracts will be accepted through **Friday, February 9, 2024.** Requests to withdraw late-breaking or clinical trials abstracts will be accepted through **Friday, February 23, 2024.** Withdrawal requests must be sent by email to abstractchanges@aacr.org. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.

Abstract Sponsorship Regulations

Expanded Abstract Sponsorship Privileges for AACR Members

Members must be in good standing in order to sponsor and endorse abstracts for presentation (see below for details). To be in good standing for the November 16 regular abstract deadline, member dues must be paid in full through 2023. To be in good standing for the January 8 late-breaking and clinical trials abstract deadline, member dues must be paid in full through 2024. Associate, Honorary, and Emeritus Members are exempt from the payment of dues; therefore, this regulation does not apply to them.

1. Each abstract submitted for presentation at the AACR Annual Meeting must be sponsored by an Active, Emeritus, Honorary, Affiliate, or Associate AACR Member in good standing (dues paid or eligibility recertified). (Student members are not eligible to sponsor an abstract.)

2. An Active, Emeritus, or Honorary Member may sponsor an unlimited number of abstracts and may use his or her sponsorship privileges in two ways: (a) to sponsor abstracts on which he or she is listed as an author, or (b) to sponsor abstracts submitted by colleagues on which he or she is not listed as an author.

3. An Associate Member in good standing may sponsor one abstract for each submission deadline provided that (a) he or she is the presenter of the abstract, and (b) an Active, Emeritus, or Honorary Member in good standing endorses the work. Active, Emeritus, and Honorary Members may endorse an unlimited number of abstracts.

4. An Affiliate Member in good standing may sponsor one abstract for each submission deadline provided that he or she is the presenter of the abstract. (Affiliate Members are not required to provide an endorser.)

5. Permission to list an AACR member as a sponsor or endorser must be obtained prior to selecting the sponsor/endorser in the Online Abstract Submission System. Individuals listed as sponsors or endorsers of abstracts will receive a notification of sponsorship or endorsement via email.

6. The sponsor must verify the content, authenticity, and quality of the abstract. Sponsorship of an abstract implies support for the data and the interpretations contained therein.

COMPLIANCE WITH THESE REGULATIONS IS THE RESPONSIBILITY OF THE AUTHORS. Adherence to these rules will be strictly enforced. Violations will result in the rejection of the abstract by the Program Committee.

Membership Application Deadlines for Abstract Sponsorship

Nonmember individuals interested in joining the AACR and sponsoring an abstract for AACR Annual Meeting 2024 must submit an application for membership no later than **November 10, 2023.** Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than **January 3, 2024.** Membership questions may be directed to membership@aacr.org.
AACR Annual Meeting Program/Navigation

AACR Annual Meeting attendees can use the following electronic and print resources to plan their itineraries and navigate the meeting:

• **Online Itinerary Planner (available January 17, 2024).** Search all AACR Annual Meeting presentations (including all proffered abstracts beginning March 5, 2024) by author/speaker, title word, and keyword and create a personal itinerary for the meeting. Personal itineraries created in the Itinerary Planner can be exported as an iCalendar file into attendees’ personal Outlook, Google Calendar, or Apple iCal applications. Itineraries can also be imported into the AACR Annual Meeting App (see below).

• **AACR Annual Meeting App (available March 15, 2024).** Attendees can carry the AACR Annual Meeting wherever they go—with or without a network connection. The AACR Annual Meeting App is available in native versions to serve users of iPhone, iPad, and Android devices and also in a browser-based version for use on most web-enabled smartphones and tablets. Once downloaded, all App content and functionality is stored locally on the user’s Apple or Android device and can be accessed without an Internet connection—including the full text of more than 6,000 abstracts. Users can search, browse, and select sessions to create a personal itinerary for the meeting. They can also import their itineraries from the Online Itinerary Planner (see above).

• **PDF Program Guide.** A PDF version of the Program Guide containing the dates, times, locations, and titles of all AACR Annual Meeting sessions will be made available on the AACR website prior to the meeting. The Program Guide also contains the names of the chairs and invited speakers in each session as well as the titles of all invited presentations. More detailed program information (including the Minisymposium and Poster Session presentations) is available in the electronic versions of the program (see above).

Please Note: As of 2024, there will no longer be a print Program Guide. Program information will be available in the online planner, the meeting app, and in PDF format.

AACR Annual Meeting Abstracts

The following electronic and print resources are available to attendees who wish to access the proffered abstracts accepted for presentation at the AACR Annual Meeting:

• **Online Proceedings/Itinerary Planner (abstracts available March 5, 2024).** The Online Proceedings/Itinerary Planner provides fully searchable access to the full text of all proffered abstracts (see above).

• **AACR Annual Meeting App (available March 15, 2024).** The full text of all proffered abstracts is stored natively in the AACR Annual Meeting App (see above).

• **PDF Proceedings (available April 1, 2024).** The PDF edition of the Proceedings of the AACR Annual Meeting contains the full text of all regular proffered abstracts (clinical trials and late-breaking abstracts are not included) and can be downloaded to devices such as the iPad, iPhone, iPod Touch, Sony Reader, and the Barnes & Noble Nook.

• **Online Supplement to Cancer Research (available March 22, 2024).** All presented abstracts will be published as an online-only supplement to the AACR journal Cancer Research. Regular abstracts will be published on March 22, 2024, and clinical trial and late-breaking abstracts will be published on April 5, 2024.

Please Note: Due to declining demand, the print Proceedings is no longer of ered for purchase to AACR Annual Meeting attendees.
The AACR Annual Meeting 2024 abstract categories, along with their related subcategories and subclassifications, are listed below. When you use the Abstract Submission System, these options will be available for your selection. Please choose the appropriate category, subcategory, and subclassification that best describe the scientific content of the abstract and the particular scientific audience you wish to reach. This information will be utilized by the members of the Program Committee in their review of abstracts and planning of sessions at the AACR Annual Meeting 2024. Please note that these abstract categories may or may not be used as AACR Annual Meeting session titles. Before making your selection, please scan the entire list for the most appropriate abstract category, subcategory, and subclassification. The regular abstract submission deadline is **November 16, 2023 (11:59 p.m. ET)** and the late-breaking and clinical trials abstract submission deadline is **January 8, 2024 (11:59 p.m. ET)**.

**BCS**  Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

**BCS01**  Bioinformatics, Computational Biology, and Systems Biology
(See also MCB08: Genomics)
- Analytic pipeline optimization
- Application of bioinformatics to cancer biology
- Artificial intelligence and machine/deep learning
- Database resources
- Integrative computational approaches
- Molecular modeling
- New algorithms
- New software tools for data analysis
- Sequence analysis
- Statistical methods
- Systems engineering
- Whole cell modeling
- Other

**BCS02**  Convergent Science
- Artificial intelligence and machine/deep learning
- Digital pathology
- Early detection and imaging
- Integration of clinical and research data
- Integrative cancer science
- Liquid biopsy; Multi-analyte and multi-omic
- Mathematical modeling
- Network biology and precision medicine
- Physical sciences in oncology
- Other

**CH**  Chemistry

**CH01**  Drug Discovery, Design, and Delivery
- Basic and applied nanotechnology and therapeutics
- Chemoinformatics, in silico screening, and computational methods
- Drug delivery
- Drug design
- High-throughput screening (assays and libraries)
- Lead identification and optimization
- Natural products
- Synthesis, metabolism, and disposition
- Targeted protein degradation
- Other

**CH02**  Proteomics and Mass Spectrometry
- Biological mass spectrometry and systems biology
- Proteomics and biomarker discovery
- Proteomics and signaling networks
- Other

**CH03**  Structural and Chemical Biology
- Chemical genetics and genomics
- Small molecule, protein, and nucleic acid interactions
- Target identification, small molecule probes, and libraries
- X-ray and NMR structures
- Other

The abstract categories are listed in alphabetical order.
<table>
<thead>
<tr>
<th>CL</th>
<th>Clinical Research (not including clinical trials, see also the Clinical Trials [CT] categories)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL01</td>
<td>Biomarkers</td>
</tr>
<tr>
<td></td>
<td>Biomarkers predictive of therapeutic benefit</td>
</tr>
<tr>
<td></td>
<td>Diagnostic biomarkers</td>
</tr>
<tr>
<td></td>
<td>Early detection biomarkers</td>
</tr>
<tr>
<td></td>
<td>Liquid biopsies: Circulating nucleic acids</td>
</tr>
<tr>
<td></td>
<td>Liquid biopsies: Circulating tumor cells</td>
</tr>
<tr>
<td></td>
<td>Metastasis biomarkers</td>
</tr>
<tr>
<td></td>
<td>Prognostic biomarkers</td>
</tr>
<tr>
<td></td>
<td>Spatial proteomics and transcriptomics</td>
</tr>
<tr>
<td>CL02</td>
<td>Biostatistics in Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>Design and analysis of clinical trials</td>
</tr>
<tr>
<td></td>
<td>New study designs: Theory, methodology, and modeling</td>
</tr>
<tr>
<td></td>
<td>Statistical modeling for cancer studies</td>
</tr>
<tr>
<td>CL03</td>
<td>Clinical Endocrinology (See also EN01: Molecular, Preclinical, and Clinical Endocrinology)</td>
</tr>
<tr>
<td></td>
<td>Endocrine-related cancers</td>
</tr>
<tr>
<td></td>
<td>Growth factors, receptors, and signal transduction</td>
</tr>
<tr>
<td></td>
<td>Hormone receptors and diagnosis/prognosis</td>
</tr>
<tr>
<td></td>
<td>Hormone signaling and inhibitors</td>
</tr>
<tr>
<td></td>
<td>Hormone synthesis, metabolism, and inhibitors</td>
</tr>
<tr>
<td></td>
<td>Neuroendocrine and other endocrine factors</td>
</tr>
<tr>
<td></td>
<td>Nuclear receptors: Structure and function</td>
</tr>
<tr>
<td></td>
<td>Preclinical studies of endocrine-related cancers</td>
</tr>
<tr>
<td></td>
<td>Receptors and signal transduction</td>
</tr>
<tr>
<td></td>
<td>Steroid hormone receptors</td>
</tr>
<tr>
<td>CL04</td>
<td>Clinical Research in the Elderly</td>
</tr>
<tr>
<td></td>
<td>Aging, immunity, and cancer</td>
</tr>
<tr>
<td>CL05</td>
<td>Clinical Research in Racial and Ethnic Minorities and Other Underserved Populations</td>
</tr>
<tr>
<td></td>
<td>Biobanking/biospecimen collection</td>
</tr>
<tr>
<td></td>
<td>Clinical trial design</td>
</tr>
<tr>
<td></td>
<td>Community-engaged research/community-based participatory research</td>
</tr>
<tr>
<td></td>
<td>Community outreach and patient accrual</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL06</td>
<td>Immuno-oncology (See also ET01: Biological Therapeutic Agents; IM01: Preclinical Immunotherapy)</td>
</tr>
<tr>
<td></td>
<td>Adoptive cell therapy</td>
</tr>
<tr>
<td></td>
<td>Combination immunotherapies</td>
</tr>
<tr>
<td></td>
<td>Immune checkpoints</td>
</tr>
<tr>
<td></td>
<td>Immune mechanisms invoked by other therapies including chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Immune mechanisms invoked by radiation therapy</td>
</tr>
<tr>
<td></td>
<td>Immune monitoring/correlates</td>
</tr>
<tr>
<td></td>
<td>Immune response to therapies</td>
</tr>
<tr>
<td></td>
<td>Immunomodulatory agents and interventions</td>
</tr>
<tr>
<td></td>
<td>Inflammation, immunity, and cancer</td>
</tr>
<tr>
<td></td>
<td>Modifiers of the tumor microenvironment</td>
</tr>
<tr>
<td></td>
<td>Therapeutic antibodies, including engineered antibodies</td>
</tr>
<tr>
<td></td>
<td>Vaccines (oncolytic and prophylactic)</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL07</td>
<td>Pediatric Cancer – Clinical Investigations (See also CT07: Phase I, II, or III Clinical Trials in Pediatric Cancer; TB06: Pediatric Cancer - Basic Science)</td>
</tr>
<tr>
<td></td>
<td>Adolescent and young adult oncology</td>
</tr>
<tr>
<td></td>
<td>Childhood cancer drug development</td>
</tr>
<tr>
<td></td>
<td>Immunotherapeutic approaches to pediatric cancer</td>
</tr>
<tr>
<td></td>
<td>Pediatric cancer predisposition and surveillance</td>
</tr>
<tr>
<td></td>
<td>Survivorship, late effects, and second cancers</td>
</tr>
<tr>
<td></td>
<td>Therapeutic dosing, resistance, and combination therapy application</td>
</tr>
<tr>
<td></td>
<td>Translational pediatric cancer research</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL08</td>
<td>Precision Oncology</td>
</tr>
<tr>
<td></td>
<td>Combination therapy</td>
</tr>
<tr>
<td></td>
<td>Molecular targeted therapy</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL09</td>
<td>Radiation Oncology (See TB07: Radiation Science; ET08: Preclinical Radiotherapeutics)</td>
</tr>
<tr>
<td></td>
<td>Clinical radiotherapeutic studies</td>
</tr>
<tr>
<td></td>
<td>Interventional radiology</td>
</tr>
<tr>
<td></td>
<td>Modification of radiosensitivity</td>
</tr>
<tr>
<td></td>
<td>Radiation therapy combinations</td>
</tr>
<tr>
<td></td>
<td>Radiation-induced late effects/second cancers</td>
</tr>
<tr>
<td></td>
<td>Radiation-induced resistance</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL10</td>
<td>Real-World Data and Real-World Evidence</td>
</tr>
<tr>
<td></td>
<td>Analyses using clinico-genomic databases</td>
</tr>
<tr>
<td></td>
<td>Clinical informatics and data science</td>
</tr>
<tr>
<td></td>
<td>Retrospective clinical analyses</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL11</td>
<td>Surgical Oncology (including Prophylactic Surgery)</td>
</tr>
<tr>
<td></td>
<td>Surgical intervention in early stage disease</td>
</tr>
<tr>
<td></td>
<td>Surgical intervention in late stage disease</td>
</tr>
<tr>
<td></td>
<td>Surgical outcomes after neoadjuvant therapy</td>
</tr>
<tr>
<td></td>
<td>Surgical palliation for local control</td>
</tr>
<tr>
<td></td>
<td>Surgical prophylaxis for high risk populations</td>
</tr>
<tr>
<td>CL12</td>
<td>Survivorship Research and Supportive Care</td>
</tr>
<tr>
<td></td>
<td>Biology of cell and tissue damage</td>
</tr>
<tr>
<td></td>
<td>Cardio-oncology</td>
</tr>
<tr>
<td></td>
<td>Comparative effectiveness research and cost-effective studies</td>
</tr>
<tr>
<td></td>
<td>Late effects of cancer and its treatment, including second cancers</td>
</tr>
<tr>
<td></td>
<td>Psycho-oncology</td>
</tr>
<tr>
<td></td>
<td>Supportive care, palliation, and pain management</td>
</tr>
<tr>
<td></td>
<td>Translational survivorship research</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CL13</td>
<td>Translational Research – Molecular Biology in Clinical Oncology (See also TB03: In Vivo Imaging and Anatomical and Molecular Pathology)</td>
</tr>
<tr>
<td></td>
<td>Clinical imaging</td>
</tr>
<tr>
<td></td>
<td>Epigenetics and clinical molecular genetics</td>
</tr>
<tr>
<td></td>
<td>Epigenetic therapy</td>
</tr>
<tr>
<td></td>
<td>Functional and molecular imaging</td>
</tr>
<tr>
<td></td>
<td>Molecular classification of tumors</td>
</tr>
<tr>
<td></td>
<td>Radiomics</td>
</tr>
<tr>
<td></td>
<td>Theranostics</td>
</tr>
<tr>
<td></td>
<td>Tumor staging: Correlation of clinical and molecular markers</td>
</tr>
<tr>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>CT</td>
<td>Clinical Trials</td>
</tr>
<tr>
<td>CT01</td>
<td>Clinical Trials in Progress</td>
</tr>
<tr>
<td></td>
<td>Phase I clinical trials in progress</td>
</tr>
<tr>
<td></td>
<td>Phase II clinical trials in progress</td>
</tr>
<tr>
<td></td>
<td>Phase III clinical trials in progress</td>
</tr>
<tr>
<td>CT02</td>
<td>Phase 0 Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>Phase 0 clinical trials</td>
</tr>
<tr>
<td>CT03</td>
<td>First-in-Human Phase I Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>First-in-human phase I clinical trials</td>
</tr>
<tr>
<td>CT04</td>
<td>Phase I Adult Clinical Trials (See also ET07: Pharmacology, Pharmacogenetics, and Pharmacogenomics)</td>
</tr>
<tr>
<td></td>
<td>Phase I adult clinical trials</td>
</tr>
<tr>
<td>CT05</td>
<td>Phase II Adult Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>Phase II adult clinical trials</td>
</tr>
<tr>
<td>CT06</td>
<td>Phase III Adult Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>Phase III adult clinical trials</td>
</tr>
<tr>
<td>CT07</td>
<td>Phase I, II, or III Clinical Trials in Pediatric Cancer (See also CL07: Pediatric Cancer Clinical Investigations; TB06: Pediatric Cancer Basic Science)</td>
</tr>
<tr>
<td></td>
<td>Phase I clinical trials in pediatric cancer</td>
</tr>
<tr>
<td></td>
<td>Phase II clinical trials in pediatric cancer</td>
</tr>
<tr>
<td></td>
<td>Phase III clinical trials in pediatric cancer</td>
</tr>
</tbody>
</table>
### ABSTRACT CATEGORIES (cont’d)

#### EN  Endocrinology

**EN01 Molecular, Preclinical, and Clinical Endocrinology**  (See also CL03: Clinical Endocrinology)
- Endocrine-related cancers
- Growth factors, receptors, and signal transduction
- Hormone receptors and diagnosis/prognosis
- Hormone signaling and inhibitors
- Hormone synthesis, metabolism, and inhibitors
- Neuroendocrine and other endocrine factors
- Nuclear receptors: Structure and function
- Preclinical studies of endocrine-related cancers
- Receptors and signal transduction
- Steroid hormone receptors

#### ET  Experimental and Molecular Therapeutics

**ET01 Biological Therapeutic Agents**  (See also CL06: Immuno-oncology; IM01: Preclinical Immunotherapy)
- Antireceptors
- Apoptosis: Therapeutic manipulation
- Growth factor receptors and other surface antigens as targets for therapy
- Oncogenes, tumor suppressor genes, and gene products as targets for therapy
- Protein kinases and phosphatases as targets for therapy
- Role of microenvironment in therapeutic response

**ET02 Drug Discovery**
- Antibody technologies
- Biochemical modulators of the therapeutic index
- Combination chemotherapies
- Differentiation therapy
- New targets
- Novel assay technology
- Novel drug delivery systems
- Targeting the tumor microenvironment in drug development

#### ET03 Drug Resistance
- Drug resistance in molecular targeted therapies
- Drug transport and metabolism
- Novel mechanisms
- Regulation of gene expression in drug resistance
- Reversal of drug resistance

#### ET04 Gene and Vector-Based Therapy
- Antisense molecules
- Gene therapy and radiation studies
- Immune modulators
- Vector systems and targeting strategies

#### ET05 Mechanisms of Drug Action
- Cell cycle mechanisms of anticancer drug action
- Cellular responses to anticancer drugs
- Role of the microenvironment in therapeutic response

#### ET06 Molecular Targets
- Cell death pathways and treatment
- DNA damage and repair
- Identification of molecular targets
- Molecular classification of tumors for diagnostics, prognostics, and therapeutic outcomes
- New nonclinical models for targets

#### ET07 Pharmacology, Pharmacogenetics, and Pharmacogenomics
- Cellular pharmacology
- Molecular pharmacology
- Pharmacogenetics and therapeutic response
- Pharmacogenomics
- Pharmacokinetics and pharmacodynamics
- Preclinical toxicology

#### ET08 Preclinical Radiotherapeutics** (See also TB07: Radiation Science; CL09: Radiation Oncology)
- Interactions of new agents with radiation
- Modification of radiosensitivity
- Molecular targets of radiation response
- Normal tissue/cellular stress responses to radiation
- Radioprotectors and radiosensitizers
- Radiotherapeutic combinations
- Theranostics/radiotheranostics

#### ET09 Small Molecule Therapeutic Agents
- DNA-reactive agents
- Epigenetic targets
- HDAC and methyltransferase inhibitors
- Molecular glues
- Novel antitumor agents
- Novel targets and pathways
- PI3K/AKT inhibitors
- Platinum complexes
- Proteasome inhibitors
- Targeted protein degraders
- Topoisomerase
- Tubulin agents
- Tyrosine kinase and phosphatase inhibitors

#### ET08 Preclinical Radiotherapeutics** (See also TB07: Radiation Science; CL09: Radiation Oncology)
- Interactions of new agents with radiation
- Modification of radiosensitivity
- Molecular targets of radiation response
- Normal tissue/cellular stress responses to radiation
- Radioprotectors and radiosensitizers
- Radiotherapeutic combinations
- Theranostics/radiotheranostics

#### ET09 Small Molecule Therapeutic Agents
- DNA-reactive agents
- Epigenetic targets
- HDAC and methyltransferase inhibitors
- Molecular glues
- Novel antitumor agents
- Novel targets and pathways
- PI3K/AKT inhibitors
- Platinum complexes
- Proteasome inhibitors
- Targeted protein degraders
- Topoisomerase
- Tubulin agents
- Tyrosine kinase and phosphatase inhibitors

#### IM  Immunology

**IM01 Preclinical Immunotherapy**  (See also CL06: Immuno-oncology; ET01: Biological Therapeutic Agents)
- Adoptive cell therapy
- Combination immunotherapies
- Immune checkpoints
- Immune mechanisms invoked by other therapies including chemotherapy
- Immune mechanisms invoked by radiation therapy
- Immune monitoring/clinical correlates
- Immune response to therapies
- Immunomodulatory agents and interventions
- Inflammation, immunity, and cancer
- Modifiers of the tumor microenvironment
- Therapeutic antibodies, including engineered antibodies
- Vaccines (oncolytic and prophylactic)

#### IM02 Tumor Immunobiology
- Adaptive immunity in tumors
- Epigenetic regulation of tumor immunity
- Inflammation and cancer: Metastasis
- Inflammation and cancer: Tumor initiation and progression
- Innate immunity to tumors
- Microbiome, inflammation, and cancer
- Novel animal models
- Oncogenic pathway-mediated regulation of inflammation and tumor immunity
- Tumor antigenicity/processing and presentation
- Tumor-induced immune suppression: Extrinsic factors
- Tumor-induced immune suppression: Intrinsic factors

#### MCB  Molecular/Cellular Biology and Genetics

**MCB01 Cell Cycle**
- CDKs and CDK inhibitors
- Cell cycle checkpoints
- Control of cell cycle progression
- Telomeres and telomerase

**MCB02 Cell Death**
- Apoptosis
- Autophagy
- Bcl-2 family proteins
- Caspases
- Effects on mitochondria/mitochondrial function
- Inhibitor of apoptosis (IAP) family proteins
- Necrosis and necroptosis
- Transcriptional control of apoptosis

### AACR ANNUAL MEETING 2024 • AOCR.org/AACR2024 • #AACR24
<table>
<thead>
<tr>
<th>RSP</th>
<th>Regulatory Science and Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSP01</td>
<td>Regulatory Science and Policy</td>
</tr>
<tr>
<td>Biosimilars and generics</td>
<td></td>
</tr>
<tr>
<td>Clinical trial design and accrual</td>
<td></td>
</tr>
<tr>
<td>Combination therapies and codescription of investigational agents and diagnostics</td>
<td></td>
</tr>
<tr>
<td>Data science and informatics</td>
<td></td>
</tr>
<tr>
<td>International regulatory issues</td>
<td></td>
</tr>
<tr>
<td>Novel endpoints and biomarkers</td>
<td></td>
</tr>
<tr>
<td>Real-world evidence and retrospective analyses</td>
<td></td>
</tr>
<tr>
<td>Tobacco and e-cigarette regulation</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SHP</th>
<th>Science and Health Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHP01</td>
<td>Science and Health Policy</td>
</tr>
<tr>
<td>Cancer disparities</td>
<td></td>
</tr>
<tr>
<td>Cancer survivorship</td>
<td></td>
</tr>
<tr>
<td>Implementation science</td>
<td></td>
</tr>
<tr>
<td>Patient advocacy and engagement</td>
<td></td>
</tr>
<tr>
<td>Value and cost issues in cancer care</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TB</th>
<th>Tumor Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB01</td>
<td>Angiogenesis</td>
</tr>
<tr>
<td>Angiogenesis and angiogenesis inhibitors</td>
<td></td>
</tr>
<tr>
<td>Host-tumor interactions</td>
<td></td>
</tr>
<tr>
<td>Molecular mechanisms of angiogenesis</td>
<td></td>
</tr>
<tr>
<td>Novel pro- and antiangiogenic factors</td>
<td></td>
</tr>
<tr>
<td>Tumor microcirculation and the microenvironment</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

| TB02 | Carcinogenesis |
| Chemical, environmental, and virus-induced carcinogenesis |
| Mutagenesis |
| Other |

| TB03 | In Vivo Imaging and Anatomical and Molecular Pathology (See also CL13: Translational Research: Molecular Biology in Clinical Oncology) |
| Advanced nanotechnology and imaging |
| Application of imaging technology to the clinic |
| Imaging in animal models |
| Imaging of molecular and cellular events in the tumor microenvironment |
| Imaging of molecular and cellular events in tumors and tumor cells |
| Imaging the immune response |
| Imaging tumor metabolism |
| New targets for imaging |
| Other |

| TB04 | Metastasis |
| Actin cytoskeleton |
| Biomarkers of metastasis |
| Epithelial/mesenchymal transition (EMT and MET) |
| Expression profiling of tumor progression and metastasis |
| Genes that regulate migration and invasion |
| Imaging of tumor progression and metastasis |
| Invasion and migration |
| Metastasis-promoting genes |
| Metastasis suppressor genes |
| Premetastatic niche |
| Therapeutic metastasis prevention |
| Other |

| TB05 | Nonclinical Models of Cancer |
| 3-D and tissue recombinant models |
| Developmental phenotypes of cancer genes |
| Human-in-mouse models of human cancer |
| Model organisms in drug discovery |
| Mouse models of human cancer |
| Noninvasive imaging in animal models |
| Organoids |
| Other animal and cell models of cancer |
| Patient-derived xenograft models |
| Zebrafish models of cancer |
| Other |

| TB06 | Pediatric Cancer - Basic Science (See also CL07: Pediatric Cancer: Clinical Investigations; CT07: Phase I, II, or III Clinical Trials in Pediatric Cancer) |
| Developmental origins and drivers of pediatric cancer |
| Pediatric cancer genomics and epigenomics |
| Pediatric cancer models |
| Pediatric cancer tumor microenvironment and tumor heterogeneity |
| Other |

| TB07 | Radiation Science |
| Modulators of radiation response |
| Photobiology/photodynamic therapy |
| Radiation dose fractionation |
| Radiation-activated signaling pathways |
| Radiation-induced gene expression |
| Radiation-induced resistance |
| Radiobiology research |
| Radioprotectors and radiosensitizers |
| Other |

| TB08 | Stem Cell Biology |
| Adult stem cells |
| Cancer stem cells |
| Developmental pathways in cancer |
| Embryonic stem cells |
| Stem cell markers |
| Stem cells and regenerative medicine in oncology |
| Other |

| TB09 | Tumor Adhesion |
| Cell adhesion and extracellular matrix |
| Drug resistance |
| Other |

| TB10 | Tumor Evolution and Heterogeneity |
| Causes and consequences of tumor heterogeneity |
| Clonal evolution |
| Methods to measure tumor evolution and heterogeneity |
| Other |

| TB11 | Tumor Microenvironment |
| Chemokines in the microenvironment |
| Drug targets in the microenvironment |
| Extracellular matrix and integrins |
| Gene expression in the microenvironment |
| Immune cells in the tumor microenvironment |
| Inflammatory cells as regulators of tumor growth |
| Microbiome |
| Organ-specific microenvironments |
| Proteases and inhibitors in the microenvironment |
| Tumor dormancy |
| Tumor/stromal interactions |
| Tumor-immune system interactions |
| Other |

ABSTRACT CATEGORIES (cont’d)

**ABSTRACT**

**CATEGORIES**

**Regular Abstract Submission Deadline:** November 16, 2023 (11:59 p.m. ET)

**Late-Breaking and Clinical Trials Abstract Submission Deadline:** January 8, 2024 (11:59 p.m. ET)
AACR MEMBERSHIP OPPORTUNITIES

AACR Membership: The Essential Association for You

With over 54,000 members in 130 countries and territories around the world and over 32% of members living outside the United States, the AACR is a dynamic and vibrant organization that offers its members opportunities to participate more fully in the global initiative to eliminate cancer. AACR membership is available to both senior and early-career investigators who conduct cancer research and related biomedical science, as well as to those health care professionals, research administrators, cancer survivors and advocates, students, and others who share the AACR’s vision and support our mission to prevent and cure cancer.

AACR membership promotes the professional growth of those in training, facilitates collaborations for established scientists, and supports everyone working in cancer research. Special rates are available to members located in countries with emerging economies as designated by the World Bank. For a complete list of countries with emerging economies, please visit AACR.org/International.

Membership Application Deadlines for Abstract Sponsorship

AACR members have the exclusive benefit of being able to sponsor and endorse abstracts for presentation at the AACR Annual Meeting. Members must be in good standing (dues paid or eligibility recertified) in order to take advantage of this member privilege. (Refer to page 27 for full details and instructions on sponsoring an abstract.)

Nonmember individuals interested in joining the AACR and sponsoring an abstract for the AACR Annual Meeting must submit an application for membership no later than November 10, 2023. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an application for membership no later than January 3, 2024.

AACR members play an integral role in achieving our mission and in advancing cancer research. We encourage our Active, Emeritus, and Honorary members to nominate colleagues, students, nurses, technicians, and others working in support of cancer research to join the AACR today!

Abstract Sponsorship

<table>
<thead>
<tr>
<th>Membership Application Deadlines</th>
<th>Abstract Submission Deadlines</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 10, 2023</td>
<td>November 16, 2022</td>
</tr>
<tr>
<td>January 3, 2024</td>
<td>January 8, 2024</td>
</tr>
</tbody>
</table>

(Late-Breaking and Clinical Trials)

Scholar Awards

<table>
<thead>
<tr>
<th>Award</th>
<th>Application Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scholar-in-Training</td>
<td>November 16, 2023</td>
</tr>
<tr>
<td>Global Scholar-in-Training</td>
<td>November 16, 2023</td>
</tr>
<tr>
<td>Minority Scholar</td>
<td>November 30, 2023</td>
</tr>
<tr>
<td>Minority and Minority-Serving Institution Faculty</td>
<td>November 30, 2023</td>
</tr>
<tr>
<td>Women in Cancer Research</td>
<td>November 30, 2023</td>
</tr>
<tr>
<td>Undergraduate Scholar</td>
<td>November 30, 2023</td>
</tr>
</tbody>
</table>

Contact the AACR Membership and Professional Development Department with any questions at 215-440-9300 or membership@aacr.org.
AACR Membership Categories

Active Membership is open to investigators who have established a record of scholarly activity resulting in original peer-reviewed articles in publications relevant to cancer research and biomedical science.

Affiliate Membership is open to qualified individuals who are health professionals working in support of cancer research and biomedical science; survivors and advocates who are members of organizations whose mission includes the advancement of cancer research; educators; or other professionals who are interested in and/or make substantial contributions to the cancer field.

Associate Membership is open to graduate students, medical students and residents, and clinical and postdoctoral fellows who are enrolled in education or training programs that could lead to careers in cancer research and the related sciences. Annual dues are not required. (Important reminder: Associate members are required to recertify their eligibility in order to remain on the member rolls. Please log into AACR.org/myAACR to retain your member exclusive benefits!)

Student Membership is open to persons who have an interest in cancer and the related biomedical sciences and who are enrolled in a program leading to a high school diploma or a bachelor’s degree. Annual dues are not required.

Emeritus Membership is open to existing Active Members who have reached the age of 70 years, who are disabled, or who are retired.

Honorary Membership is open to distinguished individuals who have made extraordinary contributions to the advancement of cancer research either through outstanding personal scientific activity or through exceptional leadership in cancer research. (Candidates for Honorary Membership are invited through a special selection process.)

Sustaining Membership is open to organizations in recognition of annual payment of dues and other substantial contributions in support of the mission and activities of the AACR. Annual dues are determined by the Sustaining Member level.

AACR Member Exclusive Benefits

Early Access to AACR Annual Meeting Housing Reservations
Tuesday, September 19, 2023, (9:00 a.m. U.S. ET) through Monday, September 25, 2023, (11:59 p.m. U.S. ET)

As a member exclusive benefit, AACR members in good standing (dues paid through December 31, 2023) are eligible to reserve hotel accommodations for the AACR Annual Meeting 2024 before reservations open to all attendees. Members may log into AACR.org/myAACR to check dues status and make a payment using the secure AACR site.

Hotel Reservations

CMR (Convention Management Resources) is the official hotel management company for the AACR Annual Meeting.

One hotel reservation is allowed per member effective September 19, 2023. Housing reservations open to the general public on September 26, 2023 (see pages 39–40). Members will need to provide the following information in order to secure a reservation:

- AACR member ID number
- Last name (as it appears in the AACR Membership records)

Members are encouraged to take advantage of early access to housing reservations before housing is made available to all attendees. Please contact the Membership and Professional Development Department at membership@aacr.org or 215-440-9300 and a membership representative will gladly assist with any questions. Not yet a member? Apply for membership at AACR.org/myAACR and join us in the global conquest of cancer.

Membership Hub

The Membership Hub is a home base for AACR members and individuals interested in becoming members. Visit the Hub to learn more about AACR’s events, programs, and activities, during the meeting. Attendees are encouraged to engage with colleagues from around the world, join Association groups, become more involved in AACR programs and activities, and share member experiences.

Membership Center

The AACR Membership Center provides a place where members can obtain information regarding their membership, join Association groups within the AACR, update contact information, pay annual dues, transfer to other categories of membership, and become familiar with new membership services.
Membership Booth at Registration

The Membership Booth in the Registration Area is a service center for AACR members to register, pay their dues, and learn more about membership during the meeting. Nonmembers are encouraged to take advantage of the special offer to join the AACR prior to registering for the meeting. Visit the Membership Booth at Registration for more details.

Member Appreciation Events

New Member Networking Mixer

The AACR is pleased to host a New Member Networking Mixer each year to welcome newly elected members into the association and provide them with an opportunity to meet and interact with the AACR leadership, network with colleagues, and forge new relationships, and learn more about exclusive member benefits and how to get involved in the association.

Celebrating AACR Long-Term Members: Member Appreciation Breakfast

The AACR is pleased to recognize those scientists who have been members of the association for 25 years and more. The AACR board of directors extends its sincere and heartfelt thanks to these members for their devotion to cancer research and long participation in and support of the AACR. Long-term members are invited to join the AACR leadership and colleagues to reconnect and share memories while enjoying breakfast.

Meet the 2024-2025 AACR President

The Meet the 2024-2025 AACR President event provides an opportunity for AACR members and Annual Meeting attendees to meet informally with the 2024-2025 AACR President, Dr. Patricia M. LoRusso, to congratulate her on her presidency and ask general questions.

AACR 50-Year Members and Honorary Members

Scientists who have reached the milestone of 50 years of AACR membership are recognized during the AACR Annual Meeting for their dedication to cancer research and continued support of AACR activities and programs. These distinguished members will be formally honored at the Annual Business Meeting of Members and celebrated throughout the meeting.

Supporting Diversity, Equity, and Inclusion

The AACR strives to support the professional development and career advancement of underrepresented minority and women scientists in cancer research. Through the efforts of AACR-Minorities in Cancer Research and AACR-Women in Cancer Research, the AACR is working to increase the number, participation, visibility, and recognition of these investigators.

AACR Minorities in Cancer Research (MICR)

Minorities in Cancer Research (MICR) is a membership group within the AACR committed to preventing and curing cancer and eradicating cancer health disparities while meeting the professional needs and advancing the careers of minority scientists. It is led by the MICR Council, which is the advisory body to the AACR leadership on issues of concern to minority investigators and is also responsible for spearheading initiatives and organizing activities of MICR through its committees.

MICR will present several exciting and engaging activities during the AACR Annual Meeting, including:

- **MICR Town Hall.** This session provides an opportunity for all attendees who support MICR to join the MICR Council in an informal discussion about current topics that have an impact on the cancer community and underrepresented minorities.

- **MICR Scientific Symposium.** This session informs the cancer research community about cancer issues related to race and ethnicity and provides a platform for minority scientists to present their work with discussion.

- **MICR Forum.** This session provides useful tools and information to support the professional development of minority cancer researchers.

- **MICR Scholar Award Programs.** Focuses on underrepresented minority early-career researchers and faculty, as well as faculty at Minority-Serving Institutions.

- **MICR Minority and Minority Serving Faculty Assembly.** This gathering will provide an open forum for early- and mid-stage investigators who are minority faculty and faculty at Minority-Serving Institutions and members of the MICR Council to meet and discuss their challenges, needs, and opportunities, and how the AACR and MICR can help with addressing them.

- **MICR Meet and Greet.** All AACR Annual Meeting attendees are invited to informally network with the MICR Council, Committee Members, and Scholar Awardees for one-on-one or group discussions.
• MICR Networking and Resource Center. The MICR Networking and Resource Center provides meeting attendees with a comfortable environment to network one-on-one and in small groups while learning about AACR and MICR programs as well as MICR membership and committee service opportunities.

• MICR Distinguished Lectureship Series. The AACR-MICR Distinguished Lectureship Series currently takes place twice a year in conjunction with the AACR Annual Meeting and again during the annual AACR Conference on the Science of Cancer Health Disparities. The intention of this series is to invite leading researchers to provide scientific presentations to faculty and students of Minority-Serving Institutions (MSIs) so as to bring the latest science directly to faculty and students on their campuses in the host city of the conference.

All Annual Meeting attendees and MICR members are invited to learn more about MICR programs, committees, and other programs of interest by visiting AACR.org/MICR or emailing micr@aacr.org. Nonmembers are welcome to visit and join.

AACR Women in Cancer Research (WICR)

Celebrating the 25th Anniversary of AACR Women in Cancer Research. Women in Cancer Research (WICR) is a membership group within the AACR committed to recognizing women's scientific achievements and fostering their career development and advancement in cancer research. It is led by the WICR Council, the advisory body to the AACR leadership on issues of concern to women investigators, which is also responsible for organizing the activities of WICR through its committees.

WICR activities taking place during the Annual Meeting include:

• Special Program Celebrating the 25th Anniversary of WICR. AACR Women in Cancer Research Council works to create more opportunities, programs, and resources to foster the overall interest and professional development of women scientists. We are delighted to expand our efforts of awareness, recognition, and professional development support during this coming year as we celebrate WICR’s 25th anniversary!


• WICR Scholar Award Program. The WICR Scholar Award supports the attendance of early-career investigators at the AACR Annual Meeting. These awards are given annually to members of Women in Cancer Research who are scientists-in-training and presenters of meritorious scientific papers at this AACR Annual Meeting.

• WICR Meet and Greet. All AACR Annual Meeting attendees are invited to informally network with the WICR Council, Committee Members, and Scholar Awardees for one-on-one or group discussions.

• WICR Networking and Resource Center. The WICR Networking and Resource Center provides meeting attendees with a comfortable environment to network one-on-one and in small groups while learning about AACR and WICR programs as well as WICR membership and committee service opportunities.

All AACR Annual Meeting attendees and WICR members are invited to learn more about WICR programs, committees, and other programs of interest by visiting AACR.org/WICR or emailing wicr@aacr.org. Nonmembers are welcome to visit and join.

Supporting AACR Associate Members (Early-Career Researchers/Scientists)

With over 29,000 Associate members, the AACR supports the education, training, and professional development of early-career researchers/scientists who are graduate students, medical students and residents, and clinical and postdoctoral fellows, in the cancer field.

The AACR Associate Member Council (AMC) are Associate members of the AACR who are elected to serve as an advisory group to the AACR leadership and to present the needs and concerns of early-career researchers/scientists. The AMC works to support the AACR’s mission to prevent and cure cancer by promoting the professional development of early-career researchers/scientists throughout the world and encouraging Associate member recruitment, retention, and engagement.

Opportunities for Associate Members During the AACR Annual Meeting 2024

Opportunities for Associate members taking place during the AACR Annual Meeting 2024 include:

• Associate Member Meet and Greet. Associate members can meet and network with other early-career attendees and Council members.

• Early-Career Associate Members 5K Team. Join the Early-Career Associate Members team and participate in the AACR Runners for Research 5K Run/Walk, build relationships among colleagues, and raise awareness and funds to support cancer research.
• Recognition and Scholar Awards. The AACR offers several scholar awards to meritorious early-career researchers residing anywhere in the world, and also to members of minority groups residing in the United States and Canada that have been traditionally underrepresented in cancer research and biomedical science, to assist them in attending the AACR Annual Meeting. Please refer to pages 22–23.

Science Education for the Next Generation of Cancer Researchers
(Opportunities for high school and undergraduate students)

AACR Undergraduate Scholar Awards
In its 27th year, this award program is highly competitive and intended to inspire young, third-year science students pursuing a bachelor’s degree to enter the field of cancer research and provide a unique educational opportunity for these students in the development of their careers in science. To learn more about this award program, visit AACR.org/UndergradAwards.

Application deadline: November 30, 2023.

19th Annual Undergraduate Student Caucus and Poster Competition
With more than 250 undergraduate student participants every year, the AACR Undergraduate Student Caucus and Poster Competition continues to be the premier event for undergraduate students attending the AACR Annual Meeting. Now in its 19th year, this program provides undergraduate students with the opportunity to learn more about current research in the cancer field, hear from investigators about educational pathways and career development, explore career options in the cancer field, and compete for the Margaret Foti Foundation Undergraduate Prizes for Cancer Research while presenting research. Undergraduates at all levels are welcome to participate in this highly anticipated program at no cost. To learn more about this exciting opportunity, please visit AACR.org/ScienceEducation or send an email to scienceeducation@aacr.org.

Registration Deadline (nonpresenting): March 15, 2024.

AACR Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers
The Special Program for High School Students promotes interactions between senior cancer scientists and promising students in order to facilitate the contributions of these students to scientific research and the conquest of cancer. Don’t miss this wonderful opportunity to learn about cancer research and careers in biomedical research and medicine. The session is free, but space is limited. Learn more at AACR.org/HighSchoolProgram.

Registration Deadline: March 15, 2024.

The AACR has over 54,000 members in 130 countries and territories around the world.
Hotel Reservations

CMR (Convention Management Resources) is the official hotel management company for the AACR Annual Meeting 2024. Hotel reservations for the AACR Annual Meeting 2024 will open at 9:00 a.m. U.S. ET on Tuesday, September 19, 2023, for all AACR members in good standing. Housing for nonmember attendees will open at 9:00 a.m. on Tuesday, September 26, 2023. The deadline for making hotel reservations is Friday, February 23, 2024. After the deadline, registrants may be required to make their own housing arrangements.

You may reserve your hotel room in one of the following ways:

**Online:** Visit the AACR Annual Meeting website at [AACR.org/AACR2024](http://AACR.org/AACR2024) to reserve your hotel room online. Please note that you must supply a credit card in order to reserve a room online. You will find descriptions, amenity information, and photographs for each AACR official hotel. Additionally, a map showing the location of all hotels and the San Diego Convention Center is available on the AACR Housing website. Visit the AACR Housing website to get up-to-the-minute availability and receive immediate confirmation of your hotel reservation.

**Phone:** AACR Housing agents will be available to accept reservations as well as provide information on the official AACR hotels Monday through Friday from 9:00 a.m. to 9:00 p.m. U.S. ET. You will be required to supply a credit card if you reserve your hotel room by phone. Once your reservation is complete, you will receive immediate confirmation by email. AACR Housing can be reached toll-free in the U.S. and Canada at 888-381-7166 or 415-979-2262. When calling AACR Housing be certain to have the following information:

- Arrival and departure dates
- Hotel preferences
- Credit card number
- Your address, phone number, fax number, and email address
- Any special requests

Guarantee

Reservations must be guaranteed with either a major credit card (AMEX, Visa, or MasterCard) or a check in the amount of $300 per guestroom and $700 per suite. Make checks payable to Convention Management Resources, Inc. If using a credit card, the card will not be charged until the check-out date. You must present a credit card upon check-in.

Changes and Cancellations

Changes and cancellations can be made:

- **Online:** Visit the AACR Housing website at [AACR.org/AACR2024](http://AACR.org/AACR2024)
- **By emailing:** [AACRSupport@cmrus.com](mailto:AACRSupport@cmrus.com)
- **By calling:** AACR Housing at 888-381-7166 or 415-979-2262
- **By faxing:** to 415-293-4397

Your credit card will be charged one night’s room plus tax or your check deposit will be forfeited if you cancel your reservation less than 72 hours before your confirmed arrival date. If you fail to arrive on the date confirmed by AACR Housing, your credit card will be charged one night’s room plus tax or your check will be forfeited. All subsequent nights of the reservation will be cancelled.

Hospitality Suites

Suites are for sleeping accommodation only and may not be used for meetings or events without prior written permission from AACR. For these types of events, please complete the AACR Affiliate Event Space Request Form. If you would like a copy of this form, please contact AACR Housing at 888-381-7166, 415-979-2262, or via email at AACRSupport@cmrus.com.
Group Reservations
Organizations wishing to hold a block of rooms must use the Group Housing Form, which can be obtained by visiting AACR.org/AACR2024 and clicking on the Housing link. Exhibitors may request rooms in the AACR room block and must submit an Exhibitor Room Block Request Form, which can be accessed from AACR.org/AACR2024. Please adhere to all rules and regulations to facilitate processing. Confirmation will be emailed.

The AACR is aware that one or more unauthorized companies are using deceptive advertising methods to direct users to fraudulent websites that purport to offer housing and registration for the AACR Annual Meeting 2024. Please note that AACR.org/AACR2024 is the only website through which users can register to attend the AACR Annual Meeting 2024 and confirm a hotel room. AACR cannot guarantee your registration or housing if you purchase using an illegitimate website.
Air Transportation
The San Diego International Airport (airport code: SAN) is the major airport in the San Diego region and offers multiple U.S. and international flights daily. San Diego is also served by Amtrak.
• Travel Office: Corporate Traveler
• Email: samantha.baron@corporatetraveler.us
• $35 service fee applies
• Business hours: Monday-Friday, 8:00 a.m. to 6:00 p.m. ET
• Emergency after hours: 215-825-3650

Assistance for International Travelers
An official letter of invitation is available through the online registration system. Contact the American Consulate in your country to review the current regulations for travel to the United States. Please begin the visa application process as early as possible. Information is available on the U.S. Department of State website at www.travel.state.gov.

Ground Transportation
Taxi Service
San Diego International Airport is located 3 miles from the San Diego Convention Center. Many companies provide taxicab service at San Diego International Airport. If you need a taxi, simply follow the signs leading to the Transportation Plazas. A Customer Service Representative will place you with the first available taxi, unless you specify a particular taxicab company.

Public Transportation
Travelers headed to and from San Diego International Airport can connect with Amtrak’s Pacific Surfliner and the COASTER at Amtrak’s Santa Fe Depot train station downtown by using Metropolitan Transit System Route 992, which operates between 5:00 a.m. and 11:30 p.m., every 15 minutes on weekdays and every 30 minutes on weekends and holidays.

The COASTER operates every day with trips throughout the day to Old Town and North San Diego County. Tickets may be purchased at ticket vending machines on the Santa Fe Depot station platform, online at GoNCTD.com, or via the COASTER Mobile App.
For additional information on connecting transit, fares, personalized travel planning, and disabled services, call 760-966-6500 or visit www.gonctd.com/coaster.
For additional information on Amtrak service in San Diego, visit the Santa Fe Depot train station, telephone 1-800-USA-RAIL, or visit www.amtrak.com or www.amtrakcalifornia.com.

Airport Shuttle
Shuttle service is available at the Transportation Plazas across from Terminals 1 and 2. From Terminal 1, cross the skybridge and take the escalators or the elevators to street level. From Terminal 2, use the pedestrian crosswalk conveniently located outside the Terminal 2 Baggage Claim Area to access the Transportation Plaza. A Customer Service Representative will place you with the first available shuttle unless you specify a particular shuttle company.
Listed below are shuttle companies frequently used by travelers. Policies, services, and rates are subject to change.

EZ Ride Shuttle
1-800-777-0585 • 858-531-8171 • EZrideshuttle.com

Sea Breeze Shuttle
619-297-7463 • Seabreezesshuttle.com

AACR Shuttle Service
The AACR will provide complimentary shuttle service over the meeting dates for all official AACR Annual Meeting hotels that are not within walking distance of the San Diego Convention Center. When available, the hotel shuttle schedule will be posted on AACR.org/Travel and will include shuttle hours of operation and the designated route number for each hotel.
Opportunities to Support the AACR Foundation

The AACR Foundation welcomes support from corporations, foundations, individuals, and other organizations that share its mission and are interested in helping to defray the costs of presenting this important international meeting on the latest developments in cancer research. For a complete list of support opportunities and their many benefits, please contact the AACR Foundation’s corporate alliances team at corporaterequests@aacr.org.

Fellows of the AACR Academy

The AACR Academy was established in 2013 to honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. Those elected, known as Fellows of the AACR Academy, constitute a global brain trust of individuals who are instrumental in advancing the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

The AACR Academy is currently led by Dr. Elizabeth M. Jaffe (2023-2025 AACR Academy President) and a Steering Committee of additional Fellows who serve as the collective voice for all Fellows of the AACR Academy, while providing ongoing advice and counsel to the AACR leadership on timely and significant scientific and policy topics as well as other matters of importance to the cancer field.

The next elected class of prestigious Fellows of the AACR Academy will be formally recognized during the AACR Annual Meeting 2024 Opening Ceremony, scheduled to take place on Sunday, April 7.

AACR Scientific Achievement Awards, Lectureships, and Prizes

Since 1961, the AACR has been proud to recognize scientific excellence across the spectrum of basic, translational, clinical, and epidemiological cancer research through a robust collection of annual awards and lectureships that serve to honor laboratory researchers, physician-scientists, and population scientists who have made significant contributions to our understanding of the diagnosis, prevention, and treatment of cancer. All annual award recipients are honored during the AACR Annual Meeting, and the majority are invited to present featured lectures during the meeting.

A complete listing of all 2024 AACR Scientific Achievement Awards and their associated nomination deadlines is provided below. Visit AACR.org/Awards to learn more and to nominate your deserving colleagues!

Extended Nomination Submission Deadline: September 30, 2023

- AACR Award for Lifetime Achievement in Cancer Research
- AACR Award for Outstanding Achievement in Basic Cancer Research
- AACR Award for Outstanding Achievement in Blood Cancer Research
- AACR Award for Outstanding Achievement in Chemistry in Cancer Research
- AACR Daniel D. Von Hof Award for Outstanding Contributions to Education and Training in Cancer Research
- AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research
- AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
Satellite Educational Symposia

Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information is available at AACR.org/AACR2024.

Registration

Online registration for the AACR Annual Meeting 2024 will open on October 24, 2023. At that time, a complete list of registration options and rates will be posted to the AACR website at AACR.org/AACR2024.

Nomination Submission Deadline: December 7, 2023

- AACR June L. Biedler Prize for Cancer Journalism
AACR ANNUAL MEETING 2024
COMMITTEES

AACR Annual Meeting Program Committee

Chairs
Keith T. Flaherty
Christina Curtis

Cochairs
Omar Abdel-Wahab
John M. Carethers
J une M. Chan
Bruce E. Clurman
Frederic J. de Sauvage
J ames V. DeGregori
Olivier Delattre
Susan M. Domchek
J ane C. Figueiredo
Thomas F. Gajewski
Cyrus M. Ghajar
Irene M. Ghobrial
Raphael Gottardo
Susan Halabi
J ames R. Heath
F. Stephen Hodi
David G. Huntsman
Stephen D. Hursting
David M. Hyman
Christine A. Iacobuzio-Donahue
Cigall Kadoch
T. Peter Kingham
Shivaani Kummar
Tak W. Mak
Lisa A. Newman
Daniel K. Nomura
Rushika M. Perera
David R. Piwnica-Worms
Charles W.M. Roberts
Melissa A. Simon
J ohn H. Stewart, IV
Elizabeth M. Swisher
Phuoc T. Tran
Marcel R.M. van den Brink
Victor E. Velculescu
Paul Workman

AACR Annual Meeting Clinical Trials Committee

Cochair
Shivaani Kummar

Members
Paolo A. Ascierto
Christian Blank
Erkut H. Borazanci
Margaret K. Callahan
Benedito A. Carneiro
Ezra E.W. Cohen
Alexander E. Drilon
Ecaterina Ileana Dumbrava
Marcus DaSilva Goncalves
Alice Y. Ho
Mustafa Khasraw
J ason J. Luke
Natalie Ngoi
Ryan J . Sullivan
Josep Taberner o
Beverly A. Teicher
Colin D. Weekes
Additional Appointments Pending

AACR Satellite Educational Symposia Committee

Appointments Pending

AACR Exhibits Committee

Chair
Wafik S. El-Deiry

Members
Ana Luisa Correia
Ekrem Emrah Er
Laura M. Heiser
Constantinos Koumenis
Amanda W. Lund
Darrion L. Mitchell
Maeva Mullooly
Rachel M. Syme
Katherine Y. Tossas
Ruoning Wang

AACR Continuing Medical Education Committee

Chair
Steven T. Rosen

Members
Bishoy M. Faltas
Antonio T. Fojo
Veronica C. Jones
Bora Lim
Jennifer W. Mack
Evan B. Shereck
Anita Villani
Evan Y. Yu
Additional Appointments Pending